<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Clin Pharmacokinet</journal-id><journal-id journal-id-type="iso-abbrev">Clin Pharmacokinet</journal-id><journal-id journal-id-type="pmc-domain-id">365</journal-id><journal-id journal-id-type="pmc-domain">springeropen</journal-id><journal-title-group><journal-title>Clinical Pharmacokinetics</journal-title></journal-title-group><issn pub-type="ppub">0312-5963</issn><issn pub-type="epub">1179-1926</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Springer</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12158833</article-id><article-id pub-id-type="pmcid-ver">PMC12158833.1</article-id><article-id pub-id-type="pmcaid">12158833</article-id><article-id pub-id-type="pmcaiid">12158833</article-id><article-id pub-id-type="pmid">40349292</article-id><article-id pub-id-type="doi">10.1007/s40262-025-01514-3</article-id><article-id pub-id-type="publisher-id">1514</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Systematic Review</subject></subj-group></article-categories><title-group><article-title>A Systematic Review and Classification of the Effects of P-glycoprotein Inhibitors and Inducers in Humans, Using Digoxin, Fexofenadine, and Dabigatran as Probe Drugs</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Coumau</surname><given-names initials="C">Claire</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-0660-082X</contrib-id><name name-style="western"><surname>Csajka</surname><given-names initials="C">Chantal</given-names></name><address><email>Chantal.csajka@chuv.ch</email></address><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/019whta54</institution-id><institution-id institution-id-type="GRID">grid.9851.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2165 4204</institution-id><institution>Center for Research and Innovation in Clinical Pharmaceutical Sciences, </institution><institution>Lausanne University Hospital and University of Lausanne, </institution></institution-wrap>Rue du Bugnon 19, 1011 Lausanne, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01swzsf04</institution-id><institution-id institution-id-type="GRID">grid.8591.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2322 4988</institution-id><institution>Institute of Pharmaceutical Sciences of Western Switzerland, </institution><institution>University of Geneva, University of Lausanne, </institution></institution-wrap>Geneva, Switzerland </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ROR">https://ror.org/01swzsf04</institution-id><institution-id institution-id-type="GRID">grid.8591.5</institution-id><institution-id institution-id-type="ISNI">0000 0001 2175 2154</institution-id><institution>School of Pharmaceutical Sciences, </institution><institution>University of Geneva, </institution></institution-wrap>Geneva, Switzerland </aff></contrib-group><pub-date pub-type="epub"><day>11</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="ppub"><year>2025</year></pub-date><volume>64</volume><issue>6</issue><issue-id pub-id-type="pmc-issue-id">490436</issue-id><fpage>849</fpage><lpage>863</lpage><history><date date-type="accepted"><day>17</day><month>4</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>11</day><month>05</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>13</day><month>06</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-06-13 00:25:26.947"><day>13</day><month>06</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; The Author(s) 2025</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p><bold>Open Access</bold> This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="40262_2025_Article_1514.pdf"/><abstract id="Abs1"><p id="Par1">P-glycoprotein is a critical efflux transporter that may significantly affect the pharmacokinetics of various drugs by influencing their absorption, distribution and elimination. While European and American regulatory guidelines provide lists of P-glycoprotein modulators, they lack specificity concerning in vivo studies and clear guidance on inducers, creating uncertainty in their clinical relevance. A systematic search on in vivo clinical studies involving healthy volunteers using fexofenadine, dabigatran and digoxin as P-glycoprotein substrates has been performed in accordance with the PRISMA guidelines. A total of 151 studies assessing the impact of P-glycoprotein modulators on the concentration&#8211;time profile of P-glycoprotein substrates were retrieved. Additionally, data on the P-glycoprotein modulators&#8217; effect on cytochrome P450 3A4 induction or inhibition were also collected. P-gp modulators were classified as potent, moderate, weak or non-interactors for P-glycoprotein, with or without cytochrome P450 3A4 impact, on the basis of the area under the concentration&#8211;time curve ratio. This classification was adapted from the Food and Drug Administration criteria for cytochrome interactions. This systematic review identified 49 area under the plasma concentration&#8211;time curve ratio&#160;values corresponding to&#160;P-glycoprotein inhibitors, 23&#160;to P-glycoprotein inducers and 131 to&#160;non-interactors. Of these, only 32.5% and 41.1% were classified as weak to potent, respectively. Only 0.7% of inhibitors and no inducers were classified as potent. This suggests that most P-glycoprotein modulators have a limited impact on drug exposure. The potential for interaction increases when P-glycoprotein modulators also affect cytochrome P450 3A4, which is the case for 59.9% of P-glycoprotein modulators. However, some moderate P-glycoprotein modulators may have clinically significant effects depending on the therapeutic margin of the substrate and the clinical context.</p><sec><title>Supplementary Information</title><p>The online version contains supplementary material available at 10.1007/s40262-025-01514-3.</p></sec></abstract><funding-group><award-group><funding-source><institution>University of Geneva</institution></funding-source></award-group><open-access><p>Open access funding provided by University of Geneva</p></open-access></funding-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#169; Springer Nature Switzerland AG 2025</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="d33e174"><title>Key Points</title><p id="Par2">
<table-wrap id="Taba" position="float" orientation="portrait"><table frame="hsides" rules="groups"><tbody><tr><td align="left" colspan="2" rowspan="1">P-gp inhibitors alone tend to have a minimal effect on P-gp substrate exposure. However, when both P-gp and CYP3A4 are involved, the risk is significantly higher, especially when CYP3A4 modulation is strong.</td></tr><tr><td align="left" colspan="2" rowspan="1">To enhance the precision of guidance for researchers and clinicians, it is advisable to refine the classification of compounds that impact both P-glycoprotein (P-gp) and CYP3A4.</td></tr><tr><td align="left" colspan="2" rowspan="1">Additionally, a more detailed categorisation of compounds that act as P-gp inducers could significantly improve the accuracy in predicting drug interactions.</td></tr><tr><td align="left" colspan="2" rowspan="1">This refined classification would facilitate a clearer understanding of the interaction dynamics, leading to more informed decision-making in clinical settings.</td></tr></tbody></table></table-wrap></p></sec><sec id="Sec2"><title>Introduction</title><p id="Par3">P-glycoprotein (P-gp) is an efflux transporter pump that plays an important role in drug transport. It was first extensively studied in oncology, where it plays a significant role in chemoresistance by actively expelling various xenobiotics from cells, thereby reducing their intracellular concentrations [<xref ref-type="bibr" rid="CR1">1</xref>&#8211;<xref ref-type="bibr" rid="CR3">3</xref>]. P-gp is expressed in a variety of organs including the small intestine, the liver, the pancreas, the kidneys [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>] and at blood&#8211;tissue barriers such as the blood&#8211;brain barrier, the blood&#8211;testis barrier and the placenta [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>]. The pharmacokinetics of numerous substrate drugs of P-gp has been shown to be influenced by P-gp inhibitors, which enhance drug absorption and reduce metabolism and elimination, resulting in an overall increase in drug exposure. Conversely, P-gp inducers have been shown to decrease drug concentrations [<xref ref-type="bibr" rid="CR8">8</xref>]. The inhibition of P-gp-mediated transport involves various mechanisms. P-gp inhibition can occur through (i) competitive inhibition, where two substrates compete for the same binding site, preventing simultaneous binding, or (ii) through non-competitive inhibition, where inhibitors bind to distinct, functionally independent sites, modulating P-gp activity indirectly, or (iii) through the blockage of ATP hydrolysis, a process essential for P-gp&#8217;s efflux function [<xref ref-type="bibr" rid="CR9">9</xref>]. While not exclusively the case, P-gp inhibitors and inducers often concurrently affect cytochrome P450 (CYP) 3A4 activity due to their similar physicochemical properties or shared regulatory pathways, which enable them to interact with both proteins [<xref ref-type="bibr" rid="CR10">10</xref>&#8211;<xref ref-type="bibr" rid="CR12">12</xref>]. The inhibition potential of P-gp and CYP 3A4 is influenced by similar structural properties: high lipophilicity and considerable molecular weight, which contribute to their binding affinity [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>], and physical proximity of the sites of action, facilitating common interactions [<xref ref-type="bibr" rid="CR10">10</xref>]. Structural properties of inducers include lipophilic and voluminous molecules (e.g. antibiotics (rifampicin, macrolides), glucocorticoids, oral antidiabetic drugs, ritonavir) with flexible conformations that allow interactions with the large ligand-binding pocket of nuclear receptors such as Pregnane X Receptor (PXR) and Constitutive Androstane Receptor (CAR). This enabled transcriptional activation of genes encoding transport proteins such as P-gp [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. As PXR and CAR also regulate CYP 3A4 expression [<xref ref-type="bibr" rid="CR17">17</xref>], compounds that induce CYP 3A4 often simultaneously induce P-gp, making a CYP 3A4 induction a predictor of P-gp induction [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Consequently, there are relatively few compounds that are specific to P-gp as substrates, inhibitors or inducers.</p><p id="Par4">In the 2000s, On the basis of the recognition that P-gp transporters are important determinants of drug exposure [<xref ref-type="bibr" rid="CR19">19</xref>&#8211;<xref ref-type="bibr" rid="CR21">21</xref>], the International Transporter Consortium (ITC) released a white paper outlining methodologies and proposing recommendations to guide preclinical and clinical studies on transporter-mediated drug interactions [<xref ref-type="bibr" rid="CR22">22</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. Following these works, the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) released in 2012 a draft guidance for drug&#8211;drug interactions (DDI) involving&#160;P-gp. These guidelines aim to determine whether a new molecular entity acts as an inhibitor or inducer, and to establish when an&#160;in vivo&#160;clinical study is necessary. The guidelines recommended digoxin as the reference P-gp probe for renal P-gp inhibition or induction, and dabigatran and fexofenadine for intestinal P-gp modulation [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. At that time, in vivo clinical studies testing for P-gp modulation were not required for drugs showing no influence on CYP3A4. In May 2023, a revised version of the FDA guidelines specified that a P-gp inhibitor is defined as a drug that demonstrates in vitro inhibition and causing a &#8805; 1.5-fold increase in the area under the concentration&#8211;time curve (AUC) of dabigatran, digoxin, or edoxaban [<xref ref-type="bibr" rid="CR26">26</xref>]. However, the revision did not provide any information on P-gp induction.</p><p id="Par5">Although DDIs involving P-gp are routinely checked in clinical practice, the risk evaluation provided by DDI software or guidelines are often based on a combination of in vitro and in vivo data, and may not consider the combined effect of the interactions involving both CYP3A4 and P-gp, which can compromise the assessment of the true risk of the interaction. There is currently no exhaustive list of P-gp inhibitors and inducers categorised by the magnitude of change in exposure in humans, a resource that would be highly valuable in clinical settings. The aim of our systematic review is to compile a comprehensive list of in vivo clinical studies on the P-gp modulatory effect of various drugs, and to classify their effect on exposure of the three P-gp substrates digoxin, fexofenadine and dabigatran.</p></sec><sec id="Sec3"><title>Materials and Methods</title><sec id="Sec4"><title>Search Strategy and Selection Criteria</title><p id="Par6">This systematic review was reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [<xref ref-type="bibr" rid="CR27">27</xref>]. The protocol was designed a priori but was not submitted to public repositories and is available upon request. Systematic literature searches were conducted in PubMed, EMBASE.com and Cochrane Central Register of Controlled Trials (Wiley) on 4 April 2022, with an update on 8 March 2024 and with the assistance of a biomedical librarian. The search terms were the following: &#8216;dabigatran&#8217;, &#8216;digoxin&#8217;, &#8216;fexofenadine&#8217;, &#8216;P-glycoprotein&#8217;, associated with &#8216;P-gp&#8217;, &#8216;ABCB1&#8217;, &#8216;MDR protein 1&#8217;, &#8216;multidrug resistance protein 1&#8217;, &#8216;multidrug transport protein 1&#8217;, &#8216;multidrug transporter 1&#8217;, &#8216;multidrug resistance transporter 1&#8217;, &#8216;ATP binding cassette subfamily b&#8217;, &#8216;ATP binding cassette subfamily b member 1&#8217;, &#8216;PGY 1 protein&#8217; and &#8216;area under the curve&#8217;, &#8216;plasma concentration-time curve&#8217;, &#8216;drug bioavailability&#8217;, &#8216;drug blood level&#8217;, &#8216;digoxin blood level&#8217;.</p><p id="Par7">Filters to exclude animal studies and conference abstracts were applied to the strategies, but no date or language limits were applied. The strategies were peer-reviewed according to the Peer Review of Electronic Search Strategies (PRESS) checklist [<xref ref-type="bibr" rid="CR28">28</xref>] by another librarian and are presented in Table <xref rid="MOESM1" ref-type="media">S1</xref>. References were imported into EndNote 20 (Clarivate&#8482;, London, UK) and deduplicated. Additional publications were identified by backward citation searching from relevant reviews and systematic reviews.</p><p id="Par8">Inclusion criteria were the following: (1) in vivo studies including healthy volunteers, (2) studies employing dabigatran, digoxin or fexofenadine as substrates to investigate the inhibitory or inductive potential of probe drugs and (3) studies reporting relevant outcome measures. Preclinical studies, including human in vitro experiments, animal data and dual publications were excluded.</p></sec><sec id="Sec5"><title>Selection Process</title><p id="Par9">One investigator (C.C.O.) conducted the study selection on the basis of titles and abstracts, using Rayyan<sup>&#174;</sup> (rayyan.qcri.org) [<xref ref-type="bibr" rid="CR29">29</xref>] to facilitate this process. Subsequently, two investigators (C.C.O. and C.C.S.) independently performed the study selection process on the basis of the full texts of the articles. In case of disagreement regarding the eligibility of a study, a discussion was undertaken until a consensus was reached.</p></sec><sec id="Sec6"><title>Qualitative Assessment</title><p id="Par10">Two investigators (C.C.O. and C.C.S.) appraised the quality of the evaluated studies using tools selected according to the study design. The Risk of Bias In Non-Randomized Studies (ROBINS-I) tool was used for non-randomized and cross-sectional studies [<xref ref-type="bibr" rid="CR30">30</xref>], while the Risk Of Bias 2 tool from the Cochrane collaboration was used for randomized studies (RoB 2.0) [<xref ref-type="bibr" rid="CR31">31</xref>]. We assessed and reported the overall risk of bias for the primary outcome, which is the area under the curve ratio (AUCR). Using the ROBINS-I tool, we evaluated biases related to result reporting, outcome measurement, missing data, deviations from intended interventions, intervention classification, participant selection and confounding. For the RoB 2.0 tool, we examined biases from randomization, deviations from intended interventions, missing outcome data, outcome measurements and selection of reported result. Using the signaling questions in the Rob 2.0 and Robins-I tools, we assessed each domain and categorised them as &#8216;low risk of bias&#8217;, &#8216;some concerns&#8217;, or &#8216;high risk of bias&#8217;. We determined an overall risk of bias for each included study on the basis of the following criteria: low risk of bias (plausible bias unlikely to seriously alter the results) if all domains were judged are at low risk; some concerns of bias (plausible bias that raises some doubt about the results) if one or more domains were some concerns; and high risk of bias (plausible bias that seriously weakens confidence in the results) if one or more domains were judged to be at high risk. We used the ClinPK checklist to evaluate the transparency and completeness of pharmacokinetic data reporting [<xref ref-type="bibr" rid="CR32">32</xref>]. Before application, two researchers (C.C.O. and C.C.S.) adapted the checklist for the included studies by removing seven unsuitable items. We then calculated the count and percentage of included studies that satisfied each item.</p></sec><sec id="Sec7"><title>Data Extraction and Synthesis</title><p id="Par11">The information on clinical studies related to P-gp inhibition and induction (i.e. study type, date, duration, substrate and interacting molecule name and dose, type of interaction (inhibition/induction), % change in AUCR) was organised using Microsoft Excel ((version 16.0), Microsoft Corporation (2016)). The AUCR, representing the geometric mean ratio (AUCR = AUC<sub>treatment</sub>/AUC<sub>control</sub>) was retrieved from the publications. To calculate the AUCR, we used reported AUC from time zero to infinity (AUC&#8320;&#8211;&#8734;) for single-dose and multiple-dose studies. If AUC&#8320;&#8211;&#8734; data were unavailable, the AUC calculated over a dosing interval at steady state (AUC&#8320;&#8211;<italic toggle="yes">&#964;</italic>) was used. These metrics were chosen as they provide equivalent information for AUCR calculation. The extracted data were reported in a spreadsheet table, one interaction per row, with literature references. Extracted data are available in Tables S2 and S3, for P-gp inhibitors and inducers, respectively.</p></sec><sec id="Sec8"><title>Data Analysis and Clinical Classification</title><p id="Par12">The cut-off values used to classify the inhibitory or inductive levels on the basis of AUCR were aligned to the FDA DDI criteria, encompassing both the criteria of P-gp inhibition and CYP inhibition and induction criteria. Drugs were classified as weak P-gp inhibitors if the AUCR was between &#8805; 1.5 to &lt; 2.0, moderate if the AUCR was between &#8805; 2.0 to &lt; 5.0 and potent if the AUCR was &#8805; 5.0. Similarly, drugs were classified as weak P-gp inducers if the AUCR was between &#8804; 0.80 and &gt; 0.50, moderate if the AUCR was between &#8804; 0.50 and &gt; 0.20 and potent if the AUCR was &#8804; 0.20. When multiple clinical trials evaluated the same inhibitor or inducer with the same substrate, the AUCR values were presented as ranges. The effects of the drugs on CYP3A4 were also included and classified into three levels: potent, moderate and weak inhibitors or inducers, according to the information provided by the FDA and EMA in each drug monography. We specifically addressed substances exhibiting time-dependent modulation effects by comparing single dose studies from those observed after multiple doses, while including the timing of the perpetrator intake and the administered doses.</p></sec></sec><sec id="Sec9"><title>Results</title><p id="Par13">We identified 1794 articles through our search. After removing 548 duplicates, 1246 records were screened, and 978 were excluded on the basis of the exclusion criteria. Of the 268 sought for retrieval, 5 could not be retrieved (full text not accessible). A total of 263 studies were assessed for eligibility, and 140 were included in review. Additionally, after backward citation searching of relevant reviews and systematic reviews, 11 more studies were included, bringing the total of 151 included studies (Fig. <xref rid="Fig1" ref-type="fig">1</xref>).<fig id="Fig1" position="float" orientation="portrait"><label>Fig. 1</label><caption><p>PRISMA flow diagram of clinical studies selection process (included and excluded studies)</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO1" position="float" orientation="portrait" xlink:href="40262_2025_1514_Fig1_HTML.jpg"/></fig></p><sec id="Sec10"><title>Qualitative Assessment</title><p id="Par14">Figures <xref rid="Fig2" ref-type="fig">2</xref> and <xref rid="Fig3" ref-type="fig">3</xref> summarise the risk of bias assessments for the randomized controlled trials (RCT) and non-randomized controlled trials (NRCT), respectively. Detailed risk of bias assessments for each included study are provided in Tables S4 and S5 for Rob 2.0 and ROBINS-I, respectively.<fig id="Fig2" position="float" orientation="portrait"><label>Fig. 2</label><caption><p>Methodological quality graph: authors&#8217; judgements on each methodological quality item, presented as percentages across all included randomized controlled trials</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO2" position="float" orientation="portrait" xlink:href="40262_2025_1514_Fig2_HTML.jpg"/></fig><fig id="Fig3" position="float" orientation="portrait"><label>Fig. 3</label><caption><p>Methodological quality graph: authors&#8217; judgements on each methodological quality item presented as percentages across all included non-randomized controlled trials</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" id="MO3" position="float" orientation="portrait" xlink:href="40262_2025_1514_Fig3_HTML.jpg"/></fig></p><p id="Par15">Regarding the transparency and completeness of reporting in the 151 clinical pharmacokinetic studies, the overall assessment indicated a high level of transparency. The lowest rate was observed in study titles, with only 40.4% of studies adequately identifying the drugs and population studied. This was followed by the description of study limitations, particularly the disclosure of potential sources of bias and imprecision, which was adequately described in only 64.9% of studies. The compliance rates with ClinPK criteria in included studies are detailed in Table <xref rid="MOESM6" ref-type="media">S6</xref>.</p><p id="Par16">Overall, 49 AUCR values (23.7%) were classified as P-gp inhibitors according to the FDA criteria of AUCR &gt; 1.5, whereas 102 AUCR values were not (49.3%). Among AUCR values&#160;classified as&#160;P-gp inhibitors, 21.2% were classified as moderate, and only one as a potent inhibitor. Four studies, which evaluated digoxin with increasing doses of inhibitors, namely itraconazole [<xref ref-type="bibr" rid="CR33">33</xref>], atorvastatin [<xref ref-type="bibr" rid="CR34">34</xref>], etanercept [<xref ref-type="bibr" rid="CR35">35</xref>] and obeticholic acid [<xref ref-type="bibr" rid="CR36">36</xref>], reported non-linear AUCR increases, indicating that P-gp inhibition reaches a saturation point at higher inhibitor concentrations. Theses results confirm previously reported data of the saturable nature of P-gp [<xref ref-type="bibr" rid="CR19">19</xref>]. Concerning P-gp inducers, none reduced the AUCR to 0.20 or below (i.e. there was no strong P-pg inducer). Nine AUCR moderately reduced to values between 0.50 and 0.20, while the majority (58.9%) showed a maximum AUCR of 0.80. The comprehensive list of all AUCR values for P-gp inhibition and induction is presented in Tables <xref rid="Tab1" ref-type="table">1</xref> and <xref rid="Tab2" ref-type="table">2</xref>, respectively. In total, 27 drugs were classified as P-gp inhibitors, and 11 as P-gp inducers.&#160;The extensive list of all AUCR values of clinical studies provided by our systematic review involving P-gp substrates when used with P-gp inhibitors or inducers classified as with and without CYP 3A4 influence, along with the reported statistical significance of AUCR values, are presented in Tables S4 and S5, respectively.<table-wrap id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Summary of P-gp inhibition levels and associated AUCR values, including the primary intestinal or renal site of action and the CYP 3A4 modulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Inhibitor</th><th align="left" colspan="1" rowspan="1">Intestinal (I) or renal (R)</th><th align="left" colspan="1" rowspan="1">Ratio AUC (AUCR) [interval] for CYP3A4 modulation<break/>FDA category</th><th align="left" colspan="1" rowspan="1">Ratio AUC (AUCR) [interval] for P-gp inhibition</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Potent P-gp inhibitors</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Indinavir/ritonavir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1"><p>5.00 (AC)</p><p>4.20 (SS)</p></td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Moderate P-gp inhibitors</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" rowspan="2" colspan="1">Clarithromycin</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">2.00</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[1.35&#8211;1.70]</td></tr><tr><td align="left" colspan="1" rowspan="1">Cobicistat</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">[2.10&#8211;2.27]</td></tr><tr><td align="left" colspan="1" rowspan="1">Darunavir/cobicistat</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1"><p>2.64 (day 4)</p><p>1.88 (day 18)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Glecaprevir and pibrentasvir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.38</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Indinavir</bold></td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">2.90</td></tr><tr><td align="left" colspan="1" rowspan="1">Itraconazole</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">[2.09&#8211;4.00]</td></tr><tr><td align="left" colspan="1" rowspan="1">Ketoconazole and fluvoxamine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">3.16</td></tr><tr><td align="left" colspan="1" rowspan="1">Lopinavir and ritonavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">[2.00&#8211;3.70]</td></tr><tr><td align="left" rowspan="2" colspan="1">Quinidine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.31</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">2.66</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1"><p>[2.08&#8211;4.56] (SD)</p><p>[2.40&#8211;3.13] (MD)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1"><p>[2.80&#8211;3.70] (AC)</p><p>[1.40&#8211;2.00] (SS)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Rolapitant</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Saquinavir and ritonavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">[1.41&#8211;2.19]</td></tr><tr><td align="left" colspan="1" rowspan="1">Valspodar</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1"><p>1.74 (SD)</p><p>3.05 (MD)</p></td></tr><tr><td align="left" rowspan="2" colspan="1">Verapamil</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">[1.30&#8211;2.87]</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[1.00&#8211;1.50]</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Weak P-gp inhibitors</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Azithromycin</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.67</td></tr><tr><td align="left" colspan="1" rowspan="1">Darunavir/ritonavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1"><p>1.72 (day 4)</p><p>1.18 (day 18)</p></td></tr><tr><td align="left" colspan="1" rowspan="1">Diosmin</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.67</td></tr><tr><td align="left" colspan="1" rowspan="1">Fluvoxamine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[1.25&#8211;2]</td><td align="left" colspan="1" rowspan="1">1.78</td></tr><tr><td align="left" colspan="1" rowspan="1">Itraconazole</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">1.68</td></tr><tr><td align="left" colspan="1" rowspan="1">Piperine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.68</td></tr><tr><td align="left" colspan="1" rowspan="1">Probenecid</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.53</td></tr><tr><td align="left" colspan="1" rowspan="1">Quercetin</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.56</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">[1.16&#8211;1.86]</td></tr><tr><td align="left" colspan="1" rowspan="1">TBAJ-876</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.51</td></tr><tr><td align="left" colspan="1" rowspan="1">Telaprevir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">1.85</td></tr><tr><td align="left" colspan="1" rowspan="1">No P-gp inhibition</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Ambrisentan</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Anacetrapib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.07</td></tr><tr><td align="left" colspan="1" rowspan="1">Aprepitant</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">0.93</td></tr><tr><td align="left" colspan="1" rowspan="1">Atorvastatin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[1.03&#8211;1.15]</td></tr><tr><td align="left" colspan="1" rowspan="1">BFE1224 (pro-drug of Ravuconazole)</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Black Cohosh</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.05</td></tr><tr><td align="left" colspan="1" rowspan="1">Bosutinib</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Breviscapine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" rowspan="2" colspan="1">Calcitriol</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.16</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Carvedilol</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.20</td></tr><tr><td align="left" colspan="1" rowspan="1">CC-90001</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.16</td></tr><tr><td align="left" rowspan="2" colspan="1">Cimetidine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">[1.25&#8211;2]</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1.26</td></tr><tr><td align="left" colspan="1" rowspan="1">Citalopram</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Combination of daclatasvir, asunaprevir and beclabuvir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.23</td></tr><tr><td align="left" rowspan="2" colspan="1">Cremophor EL</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.28</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">1.22</td></tr><tr><td align="left" colspan="1" rowspan="1">Darexaban</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Dipyridamole</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Echinacea</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.03</td></tr><tr><td align="left" colspan="1" rowspan="1">Edoxaban</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Elagolix</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.50&#8211;0.80]</td><td align="left" colspan="1" rowspan="1">1.26</td></tr><tr><td align="left" colspan="1" rowspan="1">Eliglustat</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.49</td></tr><tr><td align="left" colspan="1" rowspan="1">Entrectinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Etanercept</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[0.99&#8211;1.33]</td></tr><tr><td align="left" colspan="1" rowspan="1">Etravirine</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.19</td></tr><tr><td align="left" colspan="1" rowspan="1">Ezogabine and retigabine</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Fedratinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Felodipine</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Fermented red ginseng</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.30</td></tr><tr><td align="left" colspan="1" rowspan="1">Fostamatinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.37</td></tr><tr><td align="left" colspan="1" rowspan="1">Futibatinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Gingko biloba</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.22</td></tr><tr><td align="left" colspan="1" rowspan="1">Glecaprevir and pibrentasvir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.48</td></tr><tr><td align="left" colspan="1" rowspan="1">Goldenseal</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Grapefruit Juice</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.10</td></tr><tr><td align="left" colspan="1" rowspan="1">Isavuconazole</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.25</td></tr><tr><td align="left" colspan="1" rowspan="1">Ivacaftor</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">1.32</td></tr><tr><td align="left" colspan="1" rowspan="1">Kava Kava</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Lacosamide</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.02</td></tr><tr><td align="left" colspan="1" rowspan="1">Lanabecestat</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.14</td></tr><tr><td align="left" colspan="1" rowspan="1">Lenalidomide</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.07</td></tr><tr><td align="left" colspan="1" rowspan="1">Levetiracetam</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.04</td></tr><tr><td align="left" colspan="1" rowspan="1">Linagliptin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[1.25&#8211;2]</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Losartan</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.03</td></tr><tr><td align="left" colspan="1" rowspan="1">Maraviroc</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Maribavir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.22</td></tr><tr><td align="left" colspan="1" rowspan="1">Metronidazole</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.00</td></tr><tr><td align="left" colspan="1" rowspan="1">Midazolam</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.12</td></tr><tr><td align="left" colspan="1" rowspan="1">Midostaurin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.23</td></tr><tr><td align="left" colspan="1" rowspan="1">Mirabegron</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[1.25&#8211;2]</td><td align="left" colspan="1" rowspan="1">1.27</td></tr><tr><td align="left" rowspan="2" colspan="1">Nelfinavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" rowspan="2" colspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">1.02</td></tr><tr><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[1.20&#8211;1.23]</td></tr><tr><td align="left" colspan="1" rowspan="1">Obeticholic acid</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[1.01&#8211;1.07]</td></tr><tr><td align="left" colspan="1" rowspan="1">Omecamtiv mecarbil</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.06</td></tr><tr><td align="left" colspan="1" rowspan="1">Paroxetine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.38</td></tr><tr><td align="left" colspan="1" rowspan="1">Pexidartinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Probenecid</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.07</td></tr><tr><td align="left" colspan="1" rowspan="1">Radix Astragali extract granules</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.99</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[1.25&#8211;1.31] (SD)</td></tr><tr><td align="left" colspan="1" rowspan="1">Rivaroxaban</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.08</td></tr><tr><td align="left" colspan="1" rowspan="1">Roflumilast</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">Saquinavir and ritonavir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">1.49</td></tr><tr><td align="left" colspan="1" rowspan="1">Seralutinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Sotorasib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">1.21</td></tr><tr><td align="left" colspan="1" rowspan="1">St John's wort</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">1.28</td></tr><tr><td align="left" colspan="1" rowspan="1">Talinolol</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Telmisartan</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.22</td></tr><tr><td align="left" colspan="1" rowspan="1">Tezacaftor and ivacaftor</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">1.30</td></tr><tr><td align="left" colspan="1" rowspan="1">Ticagrelor</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.28</td></tr><tr><td align="left" colspan="1" rowspan="1">Tolvaptan</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.18</td></tr><tr><td align="left" colspan="1" rowspan="1">Troglitazone</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.04</td></tr><tr><td align="left" colspan="1" rowspan="1">Trospium chloride</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.11</td></tr><tr><td align="left" colspan="1" rowspan="1">Tucatinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.46</td></tr><tr><td align="left" colspan="1" rowspan="1">Turmeric crude extract</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Vandetanib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.23</td></tr><tr><td align="left" colspan="1" rowspan="1">Velpatasvir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.27</td></tr><tr><td align="left" colspan="1" rowspan="1">Venetoclax</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.09</td></tr><tr><td align="left" colspan="1" rowspan="1">Voclosporin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.25</td></tr><tr><td align="left" colspan="1" rowspan="1">Zanubrutinib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.50&#8211;0.80]</td><td align="left" colspan="1" rowspan="1">1.11</td></tr></tbody></table><table-wrap-foot><p>AUCR, area under the concentration curve ratio; P-gp, P-glycoprotein; CYP, cytochrome P450; SD, single dose; MD, multiple doses; AC, acute concentration = AUCR after acute dose of the interacting drug; SS, steady-state = AUCR at steady-state dosing of the interacting drug; I, acts mainly at the intestinal level with dabigatran and fexofenadine as probe P-gp substrates; R, acts mainly at the renal level, with digoxin as probe P-gp substrate</p></table-wrap-foot></table-wrap><table-wrap id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Summary of P-gp induction levels and associated AUCR values, including the primary intestinal or renal site of action and the CYP 3A4 modulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Inducer</th><th align="left" colspan="1" rowspan="1">Intestinal (I) or renal (R)</th><th align="left" colspan="1" rowspan="1">Ratio AUC (AUCR) [interval] for CYP3A4 modulation<break/>FDA category</th><th align="left" colspan="1" rowspan="1">Ratio AUC (AUCR) [interval] for P-gp induction</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1"><bold>Moderate P-gp inducers</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Carbamazepine</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[0.40&#8211;0.61]</td></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin*</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[0.33&#8211;0.59]</td></tr><tr><td align="left" colspan="1" rowspan="1"><bold>Weak P-gp inducers</bold></td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Rifampicin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[0.70&#8211;0.98]</td></tr><tr><td align="left" colspan="1" rowspan="1">Avasimibe</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.64</td></tr><tr><td align="left" colspan="1" rowspan="1">Danshen ethanol extract</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.54</td></tr><tr><td align="left" colspan="1" rowspan="1">Green tea catechins</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.67</td></tr><tr><td align="left" colspan="1" rowspan="1">Phenytoin</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">0.77</td></tr><tr><td align="left" colspan="1" rowspan="1">Ritonavir</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&gt; 5</td><td align="left" colspan="1" rowspan="1">[0.71&#8211;1.15]</td></tr><tr><td align="left" colspan="1" rowspan="1">St John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[0.74&#8211;1.01]</td></tr><tr><td align="left" colspan="1" rowspan="1">No induction</td><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">Alfentanil</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Aliskiren</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.85</td></tr><tr><td align="left" colspan="1" rowspan="1">Apararenone</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.89</td></tr><tr><td align="left" colspan="1" rowspan="1">Apple juice*</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">[0.27&#8211;0.73]</td></tr><tr><td align="left" colspan="1" rowspan="1">Bosentan</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" colspan="1" rowspan="1">Darolutamide</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Deferasirox</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[0.50&#8211;0.80]</td><td align="left" colspan="1" rowspan="1">0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Echinacea purpurea</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.98</td></tr><tr><td align="left" colspan="1" rowspan="1">Ginkgo biloba</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[0.20&#8211;0.50]</td><td align="left" colspan="1" rowspan="1">0.83</td></tr><tr><td align="left" rowspan="2" colspan="1">Grapefruit juice*</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">[0.37&#8211;0.70]</td></tr><tr><td align="left" colspan="1" rowspan="1">Hawthorn (Crataegus oxyacantha)</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.92</td></tr><tr><td align="left" colspan="1" rowspan="1">Honey</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.96</td></tr><tr><td align="left" colspan="1" rowspan="1">Letermovir</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">[2&#8211;5]</td><td align="left" colspan="1" rowspan="1">0.87</td></tr><tr><td align="left" colspan="1" rowspan="1">Milk thistle</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Odanacatib</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1">Orange*</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.31</td></tr><tr><td align="left" colspan="1" rowspan="1">Panax ginseng</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.91</td></tr><tr><td align="left" colspan="1" rowspan="1">Red ginseng</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.89</td></tr><tr><td align="left" colspan="1" rowspan="1">Sertraline</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.84</td></tr><tr><td align="left" colspan="1" rowspan="1">St John&#8217;s wort</td><td align="left" colspan="1" rowspan="1">I</td><td align="left" colspan="1" rowspan="1">&#8804; 0.20</td><td align="left" colspan="1" rowspan="1">[0.86&#8211;0.97]</td></tr><tr><td align="left" colspan="1" rowspan="1">Tea</td><td align="left" colspan="1" rowspan="1">R</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">0.99</td></tr></tbody></table><table-wrap-foot><p>AUCR, area under the concentration curve ratio; P-gp, P-glycoprotein; CYP, cytochrome P450; SD, single dose; MD, multiple doses; AC, acute concentration = AUCR after acute dose of the interacting drug; SS, steady-state = AUCR at steady-state dosing of the interacting drug; I, acts mainly at the intestinal level, dabigatran and fexofenadine are P-gp substrates; R, acts mainly at the renal level, digoxin is a P-gp substrate</p><p>*The observed AUCR reductions are primarily attributed to the OATP uptake inhibition rather than to the P-gp efflux induction</p></table-wrap-foot></table-wrap></p><p id="Par17">The distribution of AUCR values collected from the 151 clinical studies for P-gp substrates with P-gp modulators, categorised by inhibition or induction potency and CYP influence, is detailed in Table <xref rid="Tab3" ref-type="table">3</xref>. The substances exhibiting short-term inhibitory and time-dependent inductive effects&#8212;rifampicin, ritonavir, St. John&#8217;s wort, darunavir/cobicistat and darunavir/ritonavir&#8212;are detailed in Table <xref rid="Tab4" ref-type="table">4</xref>. Rifampicin initially act as a P-gp inhibitor, increasing AUCR values of digoxin (1.31&#8211;1.46) and dabigatran (2.08&#8211;2.22) probe substrates. However, after multiple doses, a reduced AUCR was observed, ranging from 0.68&#8211;1.00 for digoxin to 0.33&#8211;0.59 for dabigatran. In contrast, we observed with fexofenadine a constant inhibition after multiple doses (AUCR 2.40&#8211;3.48). This effect is predominantly due to its inhibition of renal influx transporters and OATP-mediated intestinal and hepatic uptake, which outweighs its induction properties on P-gp [<xref ref-type="bibr" rid="CR37">37</xref>]. However, a staggered administration of rifampicin with fexofenadine leads to a decrease in AUCR of 0.49, reflecting a diminished inhibitory effect and the predominance of rifampicin&#8217;s inductive effect. Similar to darunavir/cobicistat and darunavir/ritonavir, ritonavir exhibits a progressive decrease in AUCR over time, although its inhibitory effect remains predominant (AUCR 2.80 after a single dose, decreasing to 1.40 after multiple doses). However, when administered with a delay, its inductive effect becomes more pronounced (AUCR 1.15 with simultaneous multiple doses, decreasing to 0.71 with delayed administration). Ritonavir inhibits OATP uptake; however, this effect is less pronounced compared with its P-gp inhibition and induction [<xref ref-type="bibr" rid="CR38">38</xref>]. Concerning St. John&#8217;s Wort, a transient inhibitory effect is observed following a single dose (AUCR 0.99&#8211;1.28), whereas inductive properties become predominant upon repeated administration (AUCR 0.75&#8211;1.01).<table-wrap id="Tab3" position="float" orientation="portrait"><label>Table 3</label><caption><p>Distribution of AUCR values collected from the 151 clinical studies using digoxin, fexofenadine and dabigatran in the presence of P-gp inhibitors and inducers, categorised by potency and CYP3A4 influence</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2" colspan="1">AUC ratio (AUCR)</th><th align="left" colspan="2" rowspan="1">Digoxin</th><th align="left" colspan="2" rowspan="1">Fexofenadine</th><th align="left" colspan="2" rowspan="1">Dabigatran</th><th align="left" colspan="1" rowspan="1">Total</th></tr><tr><th align="left" colspan="1" rowspan="1">w<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1">w/out<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1">w<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1">w/out<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1">w<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1">w/out<break/>CYP3A4<break/><italic toggle="yes">n</italic> (%)</th><th align="left" colspan="1" rowspan="1"><italic toggle="yes">N</italic> (%)</th></tr></thead><tbody><tr><td align="left" colspan="8" rowspan="1">Inhibition</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805; 5.0 (potent)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">1 (100.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">1 (0.7)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805; 2.0 to &lt; 5.0 (moderate)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">24 (75.0)</td><td char="(" align="char" colspan="1" rowspan="1">1 (3.1)</td><td char="(" align="char" colspan="1" rowspan="1">6 (18.8)</td><td char="(" align="char" colspan="1" rowspan="1">1 (3.1)</td><td char="(" align="char" colspan="1" rowspan="1">32 (21.2)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8805; 1.5 to &lt; 2.0 (weak)</td><td char="(" align="char" colspan="1" rowspan="1">6 (37.5)</td><td char="(" align="char" colspan="1" rowspan="1">1 (6.3)</td><td char="(" align="char" colspan="1" rowspan="1">3 (18.8)</td><td char="(" align="char" colspan="1" rowspan="1">3 (18.8)</td><td char="(" align="char" colspan="1" rowspan="1">3 (18.8)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">16 (10.6)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&lt; 1.5 (no inhibition)</td><td char="(" align="char" colspan="1" rowspan="1">29 (28.4)</td><td char="(" align="char" colspan="1" rowspan="1">55 (53.9)</td><td char="(" align="char" colspan="1" rowspan="1">6 (5.9)</td><td char="(" align="char" colspan="1" rowspan="1">8 (7.8)</td><td char="(" align="char" colspan="1" rowspan="1">1 (1.0)</td><td char="(" align="char" colspan="1" rowspan="1">3 (2.9)</td><td char="(" align="char" colspan="1" rowspan="1">102 (67.5)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total</td><td char="(" align="char" colspan="1" rowspan="1">35 (23.2)</td><td char="(" align="char" colspan="1" rowspan="1">56 (37.1)</td><td char="(" align="char" colspan="1" rowspan="1">34 (22.5)</td><td char="(" align="char" colspan="1" rowspan="1">12 (7.9)</td><td char="(" align="char" colspan="1" rowspan="1">10 (6.6)</td><td char="(" align="char" colspan="1" rowspan="1">4 (2.6)</td><td char="(" align="char" colspan="1" rowspan="1">151 (100.0)</td></tr><tr><td char="." align="char" colspan="8" rowspan="1">Induction</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804; 0.20 (potent)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804; 0.50 to &gt; 0.20 (moderate)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">4 (50.0)</td><td char="(" align="char" colspan="1" rowspan="1">2 (12.5)</td><td char="(" align="char" colspan="1" rowspan="1">3 (37.5)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">9 (16.1)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&#8804; 0.80 to &gt; 0.50 (weak)</td><td char="(" align="char" colspan="1" rowspan="1">7 (46.7)</td><td char="(" align="char" colspan="1" rowspan="1">2 (13.3)</td><td char="(" align="char" colspan="1" rowspan="1">2 (13.3)</td><td char="(" align="char" colspan="1" rowspan="1">1 (13.3)</td><td char="(" align="char" colspan="1" rowspan="1">2 (13.3)</td><td char="(" align="char" colspan="1" rowspan="1">0 (0.0)</td><td char="(" align="char" colspan="1" rowspan="1">14 (25.0)</td></tr><tr><td align="left" colspan="1" rowspan="1">&#160;&gt; 0.80 (no induction)</td><td char="(" align="char" colspan="1" rowspan="1">16 (48.5)</td><td char="(" align="char" colspan="1" rowspan="1">7 (21.2)</td><td char="(" align="char" colspan="1" rowspan="1">3 (9.1)</td><td char="(" align="char" colspan="1" rowspan="1">5 (15.2)</td><td char="(" align="char" colspan="1" rowspan="1">1 (3.0)</td><td char="(" align="char" colspan="1" rowspan="1">1 (3.0)</td><td char="(" align="char" colspan="1" rowspan="1">33 (58.9)</td></tr><tr><td align="left" colspan="1" rowspan="1">Total</td><td char="(" align="char" colspan="1" rowspan="1">23 (41.1)</td><td char="(" align="char" colspan="1" rowspan="1">9 (16.1)</td><td char="(" align="char" colspan="1" rowspan="1">9 (16.1)</td><td char="(" align="char" colspan="1" rowspan="1">8 (14.3)</td><td char="(" align="char" colspan="1" rowspan="1">6 (10.7)</td><td char="(" align="char" colspan="1" rowspan="1">1 (1.8)</td><td char="(" align="char" colspan="1" rowspan="1">56 (100.0)</td></tr></tbody></table><table-wrap-foot><p>W and w/out CYP3A4 = drug with CYP3A4 or w/out CYP3A4 activity; percentages represent the proportion AUCR in each category relative to the total number of AUCR</p></table-wrap-foot></table-wrap><table-wrap id="Tab4" position="float" orientation="portrait"><label>Table 4</label><caption><p>Summary of P-gp inhibition or induction levels and associated AUCR values for drugs exhibiting time-dependent modulatory effects</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">P-gp modulator</th><th align="left" colspan="1" rowspan="1">Substrate</th><th align="left" colspan="1" rowspan="1">Substrate dose (mg/day)</th><th align="left" colspan="1" rowspan="1">Inhibitor resp. inducer dose (mg/day)</th><th align="left" colspan="1" rowspan="1">Administration Schedule</th><th align="left" colspan="1" rowspan="1">AUCR after single dose</th><th align="left" colspan="1" rowspan="1">AUCR after multiple doses</th><th align="left" colspan="1" rowspan="1"/></tr></thead><tbody><tr><td align="left" rowspan="18" colspan="1">Rifampicin (RIF)</td><td align="left" colspan="1" rowspan="1">FEX(R,S)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">450</td><td align="left" colspan="1" rowspan="1"><p>FEX: day 7</p><p>RIF: days 1&#8211;7</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"><p>(S): 3.48</p><p>(R): 3.10</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR37">37</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FEX (R,S)<sup>a</sup></td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>FEX: days 1, 3, 6</p><p>RIF: days 1&#8211;6</p></td><td align="left" colspan="1" rowspan="1"><p>(S): 4.56</p><p>(R): 3.86</p></td><td align="left" colspan="1" rowspan="1"><p>(S): 3.13</p><p>(R): 2.40</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR43">43</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FEX</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>FEX: day 7</p><p>RIF: days 1&#8211;7</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.49*</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR61">61</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">1.31</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR57">57</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: days &#8722;1, 7</p><p>RIF: days 1&#8211;6</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 1, 7</p><p>RIF: days 1&#8211;7</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR62">62</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: days &#8722;1, 7</p><p>RIF: days 1&#8211;7</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR63">63</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 1, 14</p><p>RIF: days 8&#8211;21</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"><p>1.25 (sim)</p><p>0.81 (del)</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" rowspan="3" colspan="1">DIG</td><td align="left" rowspan="3" colspan="1">0.5</td><td align="left" rowspan="3" colspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: day 28</p><p>RIF: days 1&#8211;28</p></td><td align="left" colspan="1" rowspan="1">1.46</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1"><p>DIG: day 35</p><p>RIF: days 1&#8211;28</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.68</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR66">66</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1"><p>DIG: day 42</p><p>RIF: days 1&#8211;28</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">1.00</td><td align="left" colspan="1" rowspan="1"/></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">1</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 2, 18</p><p>RIF: days 8&#8211;23</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.70</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR65">65</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">0.375</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.08</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR59">59</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">0.750</td><td align="left" colspan="1" rowspan="1">450</td><td align="left" colspan="1" rowspan="1">&#8211;</td><td align="left" colspan="1" rowspan="1">2.22</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR60">60</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">10</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 19, 37</p><p>RIF: days 9&#8211;18</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.59</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 19, 37</p><p>RIF: days 27&#8211;36</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.38</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">75</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 19, 37</p><p>RIF: days 27&#8211;36</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.33</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR18">18</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 9, 16, 23</p><p>RIF: days 2&#8211;8</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.33</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR42">42</xref>]</td></tr><tr><td align="left" rowspan="5" colspan="1">Ritonavir (RIT)</td><td align="left" colspan="1" rowspan="1">FEX</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">600 (7 days) then 800</td><td align="left" colspan="1" rowspan="1"><p>FEX: days 3, 14</p><p>RIT: days 1&#8211;14</p></td><td align="left" colspan="1" rowspan="1">2.80</td><td align="left" colspan="1" rowspan="1">1.40</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR38">38</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.4</td><td align="left" colspan="1" rowspan="1">200</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 1, 14</p><p>RIT: days 1&#8211;15</p></td><td align="left" colspan="1" rowspan="1">1.22</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR68">68</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">600</td><td align="left" colspan="1" rowspan="1"><p>DIG: day 3</p><p>RIT: days 1&#8211;11</p></td><td align="left" colspan="1" rowspan="1">1.86</td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR67">67</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.5</td><td align="left" colspan="1" rowspan="1">800</td><td align="left" colspan="1" rowspan="1"><p>DIG&#160;: day 14</p><p>RIT&#160;: days 1&#8211;14</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"><p>1.37 (sim)</p><p>1.16 (del)</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR58">58</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">100</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 14, 15</p><p>RIT: days 1&#8211;14</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">1.15 (sim) 0.71 (del)</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR69">69</xref>]</td></tr><tr><td align="left" rowspan="13" colspan="1">St John&#8217;s wort (SJW)</td><td align="left" colspan="1" rowspan="1">FEX</td><td align="left" colspan="1" rowspan="1">25</td><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1"><p>FEX: days 1, 8, 17</p><p>SJW: days 8&#8211;16</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">1.01</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR73">73</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">FEX</td><td align="left" colspan="1" rowspan="1">60</td><td align="left" colspan="1" rowspan="1">900</td><td align="left" colspan="1" rowspan="1"><p>FEX: days 1, 3, 17</p><p>SJW: days 2&#8211;17</p></td><td align="left" colspan="1" rowspan="1">1.28</td><td align="left" colspan="1" rowspan="1">0.86</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR70">70</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">120</td><td align="left" colspan="1" rowspan="1"><p>DIG: days &#8722;2, &#8722;1, 1&#8211;11</p><p>SJW: days 2&#8211;10</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.84</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR71">71</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.25</td><td align="left" colspan="1" rowspan="1">900</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 0, 14</p><p>SJW: days 1&#8211;14</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.77</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR64">64</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">DIG</td><td align="left" colspan="1" rowspan="1">0.5 (2 days), then 0.25</td><td align="left" colspan="1" rowspan="1">900</td><td align="left" colspan="1" rowspan="1"><p>DIG: days 1&#8211;15</p><p>SJW: days 6&#8211;15</p></td><td align="left" colspan="1" rowspan="1">0.99</td><td align="left" colspan="1" rowspan="1">0.75</td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR72">72</xref>]</td></tr><tr><td align="left" rowspan="8" colspan="1">DIG</td><td align="left" rowspan="8" colspan="1">0.5</td><td align="left" colspan="1" rowspan="1">20 mL</td><td align="left" rowspan="8" colspan="1"><p>DIG: days 1&#8211;21</p><p>SJW: days 8&#8211;21</p></td><td align="left" rowspan="8" colspan="1">N/A</td><td align="left" colspan="1" rowspan="1">0.92</td><td align="left" rowspan="8" colspan="1">[<xref ref-type="bibr" rid="CR74">74</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">90</td><td align="left" colspan="1" rowspan="1">0.94</td></tr><tr><td align="left" colspan="1" rowspan="1">500</td><td align="left" colspan="1" rowspan="1">1.01</td></tr><tr><td align="left" colspan="1" rowspan="1">1000</td><td align="left" colspan="1" rowspan="1">0.98</td></tr><tr><td align="left" colspan="1" rowspan="1">2000</td><td align="left" colspan="1" rowspan="1">0.82</td></tr><tr><td align="left" colspan="1" rowspan="1">2500</td><td align="left" colspan="1" rowspan="1">0.95</td></tr><tr><td align="left" colspan="1" rowspan="1">4000</td><td align="left" colspan="1" rowspan="1">0.74</td></tr><tr><td align="left" colspan="1" rowspan="1">4950</td><td align="left" colspan="1" rowspan="1">0.75</td></tr><tr><td align="left" colspan="1" rowspan="1">Darunavir (DAR)/cobicistat (COB)</td><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">800/150</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 4, 18</p><p>DAR/COB: days 4, 5&#8211;20</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"><p>2.64 (day 4)</p><p>1.88 (day 18)</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr><tr><td align="left" colspan="1" rowspan="1">Darunavir (DAR)/ritonavir (RIT)</td><td align="left" colspan="1" rowspan="1">DAB</td><td align="left" colspan="1" rowspan="1">150</td><td align="left" colspan="1" rowspan="1">800/100</td><td align="left" colspan="1" rowspan="1"><p>DAB: days 1, 4, 18</p><p>DAR/RIT: days 4, 5&#8211;20</p></td><td align="left" colspan="1" rowspan="1">N/A</td><td align="left" colspan="1" rowspan="1"><p>1.72 (day 4)</p><p>1.18 (day 18)</p></td><td align="left" colspan="1" rowspan="1">[<xref ref-type="bibr" rid="CR75">75</xref>]</td></tr></tbody></table><table-wrap-foot><p>DIG, digoxin; FEX, fexofenadine; DAB, dabigatran; RIF, rifampicin; RIT, ritonavir; DAR, darunavir; COB, cobicistat; day X, duration of inducer and substrate co-administration; sim, simultaneous intake; del, delayed intake; N/A, no available value</p><p>*Decrease in AUCR observed after staggered rifampicin administration; <sup>a</sup>R and S enantiomers</p></table-wrap-foot></table-wrap></p><p id="Par18">Our results revealed that in the CYP3A4-influenced group, percentage of the AUCR &#8805; 2.0 or &#8804; 0.5 was 38.0% and 18.4% for inhibitors and inducers, respectively, and 2.8% respectively. 11.1% for the group without CYP 3A4 influence.</p></sec></sec><sec id="Sec11"><title>Discussion</title><p id="Par19">To the best of our knowledge, this study is the first systematic review to comprehensively list all P-gp inhibitors and inducers investigated in clinical trials involving healthy volunteers and to classify these interactors on the basis of their AUCR.</p><p id="Par20">Our review of 151 clinical studies, including 69 RCTs and 82 NRCTs, revealed that most P-gp inhibitors and inducers have a limited impact on drug exposure. The majority (97%) of P-gp inhibitors only act as weak to no interactors in human studies. A minority of compounds with a sole effect on P-gp were classified as moderate inhibitors, resulting in a maximum AUCR of 3.05; the AUCR was, however, greater than 5.0 for compounds inhibiting both P-gp and CYP 3A4. With regard to P-gp induction, no AUCR reductions for sole P-gp inducers were below 0.20. Only two tested compounds were classified as moderate inducer (AUCR ranging from 0.20 to 0.50) and the remaining majority showed no inductive properties.</p><p id="Par21">Our findings are consistent with other studies suggesting the moderate influence of drugs on P-gp inhibition, with AUCR values increasing from 1.2 to 2.0 [<xref ref-type="bibr" rid="CR39">39</xref>, <xref ref-type="bibr" rid="CR40">40</xref>]. Likewise, the limited influence of P-gp induction found in our study&#8212;a maximal decrease in AUCR to 0.27&#8212;is in good agreement with the study by Elmeliegly et al., who reported a modest decrease in digoxin AUCR ranging from 0.80 to 0.33 with rifampicin and from 0.88 to 0.58 with carbamazepine [<xref ref-type="bibr" rid="CR41">41</xref>]. These results indicate that P-gp induction typically reduces substrate exposure by one category less than CYP3A4 induction if based on the same classification system [<xref ref-type="bibr" rid="CR41">41</xref>]. As previously mentioned, P-gp induction is regulated by transcriptional activation through nuclear receptor that also regulates CYP 3A4 expression [<xref ref-type="bibr" rid="CR17">17</xref>]. This shared regulatory pathway explains why CYP3A4 inducers are often co-inducers of P-gp, although the magnitude of induction may differ [<xref ref-type="bibr" rid="CR18">18</xref>]. Limited in vivo data suggest that transporters such as P-gp are generally less inducible than enzymes, including CYP3A4 [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR42">42</xref>].</p><p id="Par22">A particular case was observed with rifampicin, which appears to act as both a strong inhibitor and inducer, depending on the timing and context of its administration. Kusuhara et al. [<xref ref-type="bibr" rid="CR43">43</xref>] demonstrated that a single or simultaneous administration of rifampicin with fexofenadine increased fexofenadine AUCR by more than three-fold, whereas separate or multiple administration of rifampicin led to a reduction in fexofenadine&#8217;s exposure. The simultaneous administration of rifampicin and fexofenadine primarily drives the intestinal P-gp inhibition, causing an increase in fexofenadine&#8217;s bioavailability and AUC. Rifampicin inhibition may also be related to inhibition of both intestinal and renal P-gp as well as organic anion-transporting polypeptides (OATP), responsible for the reduction of drug absorption, metabolisation and excretion. After multiple dosing and induction of the Pregnane X Receptor, rifampicin induction of P-gp and OATP dominates, shifting its role from an inhibitor to an inducer.<sup>43</sup> Fexofenadine, also known to be a substrate of OATP transporters [<xref ref-type="bibr" rid="CR44">44</xref>], is particularly affected by these modulation mechanisms. The same observation, although to a lesser extent, was observed for ritonavir [<xref ref-type="bibr" rid="CR45">45</xref>], which demonstrated a more substantial inhibitory effect compared with its inducing effect [<xref ref-type="bibr" rid="CR46">46</xref>], St John&#8217;s wort (Hypericum perforatum) and darunavir/cobicistat and darunavir/ritonavir [<xref ref-type="bibr" rid="CR47">47</xref>&#8211;<xref ref-type="bibr" rid="CR49">49</xref>].</p><p id="Par23">In this study, we chose to classify P-gp inhibitors and inducers into three levels of intensity, as proposed by the FDA guidelines to be aligned with the CYP categorisation. Given the modest effect of P-gp inhibitors alone on drug exposure, the binary classification of the FDA for P-gp inhibitors&#8212;AUCR &lt; 1.5 and &#8805; 1.5&#8212;could be appropriate. Yet, for compounds that inhibit or induce both P-gp and CYP3A4, a more nuanced three-tiered classification system would provide a more accurate quantification of the interaction potential. Additionally, neither the EMA nor the FDA provide any specific recommendations for P-gp induction studies or categorisation guidelines. On the basis of the present results, we could suggest using an AUCR cut-off of &#8804; 0.50 to indicate a significant (moderate to major) P-gp induction, while an AUCR of &gt; 0.50 would represent a minor P-gp induction. A guidance for P-gp and/or CYP induction classification would ensure a better alignment with the classifications used for inhibitors and offer clearer guidance for both researchers and clinicians.</p><p id="Par24">From a clinical perspective, P-gp inhibitors alone tend to have minimal effect on P-gp substrate exposure, but when both P-gp and CYP3A4 are involved, the risk is significantly higher, especially when CYP3A4 modulation is strong. P-gp and CYP3A4 work synergistically to limit the intracellular accumulation of xenobiotics. The efflux of substrates by P-gp reduces the risk of exceeding the metabolic capacity of intracellular CYP enzymes, facilitating repeated substrate entry and efflux, thereby creating an efficient protective cycle. This mechanism, regulated by the PXR and retinoid X receptor (RXR), highlights the co-evolution of this vital defense system against potentially toxic compounds [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par25">The clinical relevance of DDIs depends on the magnitude of the DDI effect, but also on additional factors. They include pharmacokinetic determinants such as protein binding, route of administration, drug&#8211;receptor interactions and therapeutic range. In addition, patient-specific variables, such as organ function (e.g. hepatic and renal impairment), age and comorbidities, play a critical role in determining the clinical impact of DDIs. Genetic polymorphisms in the ABCB1 gene, which encodes P-gp, may also impact the expression of P-gp transporters [<xref ref-type="bibr" rid="CR50">50</xref>]. The complex interplay among these factors must be carefully considered in clinical practice to ensure a precise evaluation of the risk&#8211;benefit balance of a given interaction [<xref ref-type="bibr" rid="CR51">51</xref>].</p><p id="Par26">Our findings indicate that, for three drugs evaluated with both intestinal and renal P-gp substrates (clarithromycin, verapamil and grapefruit juice), AUCR values&#8212;and consequently, the classification of modulation&#8212;varied depending on the site of P-gp interaction. This complexity arises because a modulator acting predominantly at the intestinal level may have a limited impact on a renal P-gp substrate, and vice versa. Although the affinity of substrates and modulators for intestinal or renal P-gp should also be considered when interpreting the overall clinical impact of P-gp-mediated interactions, such information may not always be readily accessible in routine clinical settings.</p><p id="Par27">Our comprehensive search of DDI involving P-gp has several limitations that should be mentioned. First, our study was limited to clinical studies using dabigatran, digoxin and fexofenadine, as previously recommended by the FDA and EMA guidelines at the time of data collection [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Since 2023, the FDA guidelines recommend using edoxaban instead of fexofenadine as a P-gp probe due to fexofenadine's lack of specificity for P-gp, as it is also a substrate of OATP [<xref ref-type="bibr" rid="CR44">44</xref>]. DDI evaluation in healthy volunteers using edoxaban has recently been conducted, indicating that, according to our study classification, dronedarone (AUCR 1.85) and quinidine (AUCR 1.77) are weak P-gp inhibitors and amiodarone (AUCR 1.40) has no influence on P-gp [<xref ref-type="bibr" rid="CR52">52</xref>]. Second, several well-recognised P-gp inhibitors are missing from our systematic review, primarily due to the absence of published studies in healthy volunteers within the primary literature or because clinical studies were conducted using substrates not recognised by the FDA guidance. These include ciclosporin with a reported AUCR of 1.78 indicating modest P-gp inhibition [<xref ref-type="bibr" rid="CR53">53</xref>] and fluoxetine [<xref ref-type="bibr" rid="CR54">54</xref>], erythromycin [<xref ref-type="bibr" rid="CR55">55</xref>] and the P-gp inducer valproic acid [<xref ref-type="bibr" rid="CR56">56</xref>], for which no exposure values are available in the literature.</p><p id="Par28">In conclusion, our systematic review provides a substantial basis for quantifiying P-gp interactions, which remains to be mostly clinically relevant for drugs inhibiting both P-gp and cytochromes. The proposed categorisation of the interaction potential based on clinical exposure assessed in robust clinical trials can be useful to inform safer co-prescription practices.</p></sec><sec id="Sec12" sec-type="supplementary-material"><title>Supplementary Information</title><p>Below is the link to the electronic supplementary material.<supplementary-material content-type="local-data" id="MOESM1" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM1_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file1 (DOCX 19 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM2" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM2_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file2 (DOCX 272 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM3" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM3_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file3 (DOCX 106 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM4" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM4_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file4 (DOCX 225 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM5" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM5_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file5 (DOCX 308 KB)</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="MOESM6" position="float" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="40262_2025_1514_MOESM6_ESM.docx" position="float" orientation="portrait"><caption><p>Supplementary file6 (DOCX 16 KB)</p></caption></media></supplementary-material></p></sec></body><back><ack><p>We would like to thank C&#233;cile Jaques from the Medical Library, Lausanne University Hospital and University of Lausanne, Switzerland for helping us conduct our literature search.</p></ack><notes><title>Declarations</title><notes id="FPar1" notes-type="funding"><title>Funding</title><p id="Par29">Open access funding provided by University of Geneva.</p></notes><notes id="FPar2" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par30">Claire Coumau and Chantal Csajka declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.</p></notes><notes id="FPar3" notes-type="author-contribution"><title>Author contributions</title><p id="Par31">C.C.O. and C.C.S. contributed to the concept and design of the systematic review. C.C.O. performed the literature search, data extraction, analysis, risk of bias assessment of the studies, and writing. C.C.S. contributed to the risk of bias assessment of the studies, and revised the manuscript critically. All authors contributed to the article and approved the submitted version.</p></notes><notes id="FPar4"><title>Data availability statement</title><p id="Par32">Data sharing not applicable to this article as no datasets were generated or analysed during the current study.</p></notes><notes id="FPar5"><title>Ethics approval</title><p id="Par33">Not applicable.</p></notes><notes id="FPar6"><title>Code availability</title><p id="Par34">Not applicable.</p></notes><notes id="FPar7"><title>Consent to participate</title><p id="Par35">Not applicable.</p></notes><notes id="FPar8"><title>Consent for publication</title><p id="Par36">Not applicable.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><citation-alternatives><element-citation id="ec-CR1" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>List</surname><given-names>AF</given-names></name></person-group><article-title>Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia</article-title><source>Leukemia</source><year>1996</year><volume>10</volume><issue>6</issue><fpage>937</fpage><lpage>942</lpage><pub-id pub-id-type="pmid">8667648</pub-id></element-citation><mixed-citation id="mc-CR1" publication-type="journal">List AF. Role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia. 1996;10(6):937&#8211;42.<pub-id pub-id-type="pmid">8667648</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR2"><label>2.</label><citation-alternatives><element-citation id="ec-CR2" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Billson</surname><given-names>AL</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>JB</given-names></name><name name-style="western"><surname>Walker</surname><given-names>DA</given-names></name><name name-style="western"><surname>Lowe</surname><given-names>J</given-names></name></person-group><article-title>Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults</article-title><source>Br J Neurosurg</source><year>1994</year><volume>8</volume><issue>5</issue><fpage>585</fpage><lpage>591</lpage><pub-id pub-id-type="doi">10.3109/02688699409002952</pub-id><pub-id pub-id-type="pmid">7857540</pub-id></element-citation><mixed-citation id="mc-CR2" publication-type="journal">Billson AL, Palmer JB, Walker DA, Lowe J. Multidrug resistance gene (MDR 1) expression in neuro-axial tumours of children and young adults. Br J Neurosurg. 1994;8(5):585&#8211;91.<pub-id pub-id-type="pmid">7857540</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/02688699409002952</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR3"><label>3.</label><citation-alternatives><element-citation id="ec-CR3" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartner</surname><given-names>N</given-names></name><name name-style="western"><surname>Riordan</surname><given-names>JR</given-names></name><name name-style="western"><surname>Ling</surname><given-names>V</given-names></name></person-group><article-title>Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines</article-title><source>Science</source><year>1983</year><volume>221</volume><issue>4617</issue><fpage>1285</fpage><lpage>1288</lpage><pub-id pub-id-type="doi">10.1126/science.6137059</pub-id><pub-id pub-id-type="pmid">6137059</pub-id></element-citation><mixed-citation id="mc-CR3" publication-type="journal">Kartner N, Riordan JR, Ling V. Cell surface P-glycoprotein associated with multidrug resistance in mammalian cell lines. Science. 1983;221(4617):1285&#8211;8.<pub-id pub-id-type="pmid">6137059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.6137059</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR4"><label>4.</label><citation-alternatives><element-citation id="ec-CR4" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thiebaut</surname><given-names>F</given-names></name><name name-style="western"><surname>Tsuruo</surname><given-names>T</given-names></name><name name-style="western"><surname>Hamada</surname><given-names>H</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>MM</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>MC</given-names></name></person-group><article-title>Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues</article-title><source>Proc Natl Acad Sci USA</source><year>1987</year><volume>84</volume><issue>21</issue><fpage>7735</fpage><lpage>7738</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.21.7735</pub-id><pub-id pub-id-type="pmid">2444983</pub-id><pub-id pub-id-type="pmcid">PMC299375</pub-id></element-citation><mixed-citation id="mc-CR4" publication-type="journal">Thiebaut F, Tsuruo T, Hamada H, Gottesman MM, Pastan I, Willingham MC. Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues. Proc Natl Acad Sci USA. 1987;84(21):7735&#8211;8.<pub-id pub-id-type="pmid">2444983</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.84.21.7735</pub-id><pub-id pub-id-type="pmcid">PMC299375</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR5"><label>5.</label><citation-alternatives><element-citation id="ec-CR5" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fojo</surname><given-names>AT</given-names></name><name name-style="western"><surname>Ueda</surname><given-names>K</given-names></name><name name-style="western"><surname>Slamon</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Poplack</surname><given-names>D</given-names></name><name name-style="western"><surname>Gottesman</surname><given-names>M</given-names></name><name name-style="western"><surname>Pastan</surname><given-names>I</given-names></name></person-group><article-title>Expression of a multidrug-resistance gene in human tumors and tissues</article-title><source>Proc Natl Acad Sci</source><year>1987</year><volume>84</volume><issue>1</issue><fpage>265</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.1.265</pub-id><pub-id pub-id-type="pmid">2432605</pub-id><pub-id pub-id-type="pmcid">PMC304184</pub-id></element-citation><mixed-citation id="mc-CR5" publication-type="journal">Fojo AT, Ueda K, Slamon DJ, Poplack D, Gottesman M, Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci. 1987;84(1):265&#8211;9.<pub-id pub-id-type="pmid">2432605</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.84.1.265</pub-id><pub-id pub-id-type="pmcid">PMC304184</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR6"><label>6.</label><citation-alternatives><element-citation id="ec-CR6" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fromm</surname><given-names>MF</given-names></name></person-group><article-title>Importance of P-glycoprotein at blood-tissue barriers</article-title><source>Trends Pharmacol Sci</source><year>2004</year><volume>25</volume><issue>8</issue><fpage>423</fpage><lpage>429</lpage><pub-id pub-id-type="doi">10.1016/j.tips.2004.06.002</pub-id><pub-id pub-id-type="pmid">15276711</pub-id></element-citation><mixed-citation id="mc-CR6" publication-type="journal">Fromm MF. Importance of P-glycoprotein at blood-tissue barriers. Trends Pharmacol Sci. 2004;25(8):423&#8211;9.<pub-id pub-id-type="pmid">15276711</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.tips.2004.06.002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR7"><label>7.</label><citation-alternatives><element-citation id="ec-CR7" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name><name name-style="western"><surname>Jonker</surname><given-names>JW</given-names></name></person-group><article-title>Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview</article-title><source>Adv Drug Deliv Rev</source><year>2003</year><volume>55</volume><issue>1</issue><fpage>3</fpage><lpage>29</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(02)00169-2</pub-id><pub-id pub-id-type="pmid">12535572</pub-id></element-citation><mixed-citation id="mc-CR7" publication-type="journal">Schinkel AH, Jonker JW. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev. 2003;55(1):3&#8211;29.<pub-id pub-id-type="pmid">12535572</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(02)00169-2</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR8"><label>8.</label><citation-alternatives><element-citation id="ec-CR8" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Balayssac</surname><given-names>D</given-names></name><name name-style="western"><surname>Authier</surname><given-names>N</given-names></name><name name-style="western"><surname>Cayre</surname><given-names>A</given-names></name><name name-style="western"><surname>Coudore</surname><given-names>F</given-names></name></person-group><article-title>Does inhibition of P-glycoprotein lead to drug&#8211;drug interactions?</article-title><source>Toxicol Lett</source><year>2005</year><volume>156</volume><issue>3</issue><fpage>319</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1016/j.toxlet.2004.12.008</pub-id><pub-id pub-id-type="pmid">15763631</pub-id></element-citation><mixed-citation id="mc-CR8" publication-type="journal">Balayssac D, Authier N, Cayre A, Coudore F. Does inhibition of P-glycoprotein lead to drug&#8211;drug interactions? Toxicol Lett. 2005;156(3):319&#8211;29.<pub-id pub-id-type="pmid">15763631</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.toxlet.2004.12.008</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR9"><label>9.</label><citation-alternatives><element-citation id="ec-CR9" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mollazadeh</surname><given-names>S</given-names></name><name name-style="western"><surname>Sahebkar</surname><given-names>A</given-names></name><name name-style="western"><surname>Hadizadeh</surname><given-names>F</given-names></name><name name-style="western"><surname>Behravan</surname><given-names>J</given-names></name><name name-style="western"><surname>Arabzadeh</surname><given-names>S</given-names></name></person-group><article-title>Structural and functional aspects of P-glycoprotein and its inhibitors</article-title><source>Life Sci</source><year>2018</year><volume>214</volume><fpage>118</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.1016/j.lfs.2018.10.048</pub-id><pub-id pub-id-type="pmid">30449449</pub-id></element-citation><mixed-citation id="mc-CR9" publication-type="journal">Mollazadeh S, Sahebkar A, Hadizadeh F, Behravan J, Arabzadeh S. Structural and functional aspects of P-glycoprotein and its inhibitors. Life Sci. 2018;214:118&#8211;23.<pub-id pub-id-type="pmid">30449449</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.lfs.2018.10.048</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR10"><label>10.</label><citation-alternatives><element-citation id="ec-CR10" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Cummins</surname><given-names>CL</given-names></name></person-group><article-title>The drug efflux-metabolism alliance: biochemical aspects</article-title><source>Adv Drug Deliv Rev</source><year>2001</year><volume>50</volume><issue>Suppl 1</issue><fpage>S3</fpage><lpage>11</lpage><pub-id pub-id-type="doi">10.1016/S0169-409X(01)00178-8</pub-id><pub-id pub-id-type="pmid">11576692</pub-id></element-citation><mixed-citation id="mc-CR10" publication-type="journal">Benet LZ, Cummins CL. The drug efflux-metabolism alliance: biochemical aspects. Adv Drug Deliv Rev. 2001;50(Suppl 1):S3-11.<pub-id pub-id-type="pmid">11576692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0169-409x(01)00178-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR11"><label>11.</label><citation-alternatives><element-citation id="ec-CR11" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wacher</surname><given-names>VJ</given-names></name><name name-style="western"><surname>Wu</surname><given-names>CY</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name></person-group><article-title>Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy</article-title><source>Mol Carcinog</source><year>1995</year><volume>13</volume><issue>3</issue><fpage>129</fpage><lpage>134</lpage><pub-id pub-id-type="doi">10.1002/mc.2940130302</pub-id><pub-id pub-id-type="pmid">7619215</pub-id></element-citation><mixed-citation id="mc-CR11" publication-type="journal">Wacher VJ, Wu CY, Benet LZ. Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein: implications for drug delivery and activity in cancer chemotherapy. Mol Carcinog. 1995;13(3):129&#8211;34.<pub-id pub-id-type="pmid">7619215</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mc.2940130302</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR12"><label>12.</label><citation-alternatives><element-citation id="ec-CR12" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schuetz</surname><given-names>EG</given-names></name><name name-style="western"><surname>Beck</surname><given-names>WT</given-names></name><name name-style="western"><surname>Schuetz</surname><given-names>JD</given-names></name></person-group><article-title>Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells</article-title><source>Mol Pharmacol</source><year>1996</year><volume>49</volume><issue>2</issue><fpage>311</fpage><lpage>318</lpage><pub-id pub-id-type="doi">10.1016/S0026-895X(25)08713-9</pub-id><pub-id pub-id-type="pmid">8632764</pub-id></element-citation><mixed-citation id="mc-CR12" publication-type="journal">Schuetz EG, Beck WT, Schuetz JD. Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol Pharmacol. 1996;49(2):311&#8211;8.<pub-id pub-id-type="pmid">8632764</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR13"><label>13.</label><citation-alternatives><element-citation id="ec-CR13" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>RB</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>CL</given-names></name><name name-style="western"><surname>Lien</surname><given-names>LL</given-names></name><name name-style="western"><surname>Lien</surname><given-names>EJ</given-names></name></person-group><article-title>Structure&#8211;activity relationship: analyses of p-glycoprotein substrates and inhibitors</article-title><source>J Clin Pharm Ther</source><year>2003</year><volume>28</volume><issue>3</issue><fpage>203</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1046/j.1365-2710.2003.00487.x</pub-id><pub-id pub-id-type="pmid">12795780</pub-id></element-citation><mixed-citation id="mc-CR13" publication-type="journal">Wang RB, Kuo CL, Lien LL, Lien EJ. Structure&#8211;activity relationship: analyses of p-glycoprotein substrates and inhibitors. J Clin Pharm Ther. 2003;28(3):203&#8211;28.<pub-id pub-id-type="pmid">12795780</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.1365-2710.2003.00487.x</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR14"><label>14.</label><citation-alternatives><element-citation id="ec-CR14" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kiani</surname><given-names>YS</given-names></name><name name-style="western"><surname>Jabeen</surname><given-names>I</given-names></name></person-group><article-title>Exploring the chemical space of cytochrome P450 inhibitors using integrated physicochemical parameters, drug efficiency metrics and decision tree models</article-title><source>Computation</source><year>2019</year><volume>7</volume><issue>2</issue><fpage>26</fpage><pub-id pub-id-type="doi">10.3390/computation7020026</pub-id></element-citation><mixed-citation id="mc-CR14" publication-type="journal">Kiani YS, Jabeen I. Exploring the chemical space of cytochrome P450 inhibitors using integrated physicochemical parameters, drug efficiency metrics and decision tree models. Computation. 2019;7(2):26.</mixed-citation></citation-alternatives></ref><ref id="CR15"><label>15.</label><citation-alternatives><element-citation id="ec-CR15" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kliewer</surname><given-names>SA</given-names></name><name name-style="western"><surname>Goodwin</surname><given-names>B</given-names></name><name name-style="western"><surname>Willson</surname><given-names>TM</given-names></name></person-group><article-title>The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism</article-title><source>Endocr Rev</source><year>2002</year><volume>23</volume><issue>5</issue><fpage>687</fpage><lpage>702</lpage><pub-id pub-id-type="doi">10.1210/er.2001-0038</pub-id><pub-id pub-id-type="pmid">12372848</pub-id></element-citation><mixed-citation id="mc-CR15" publication-type="journal">Kliewer SA, Goodwin B, Willson TM. The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr Rev. 2002;23(5):687&#8211;702.<pub-id pub-id-type="pmid">12372848</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1210/er.2001-0038</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR16"><label>16.</label><citation-alternatives><element-citation id="ec-CR16" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Willson</surname><given-names>TM</given-names></name><name name-style="western"><surname>Kliewer</surname><given-names>SA</given-names></name></person-group><article-title>PXR, CAR and drug metabolism</article-title><source>Nat Rev Drug Discov</source><year>2002</year><volume>1</volume><issue>4</issue><fpage>259</fpage><lpage>266</lpage><pub-id pub-id-type="doi">10.1038/nrd753</pub-id><pub-id pub-id-type="pmid">12120277</pub-id></element-citation><mixed-citation id="mc-CR16" publication-type="journal">Willson TM, Kliewer SA. PXR, CAR and drug metabolism. Nat Rev Drug Discov. 2002;1(4):259&#8211;66.<pub-id pub-id-type="pmid">12120277</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd753</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR17"><label>17.</label><citation-alternatives><element-citation id="ec-CR17" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YM</given-names></name><name name-style="western"><surname>Ong</surname><given-names>SS</given-names></name><name name-style="western"><surname>Chai</surname><given-names>SC</given-names></name><name name-style="western"><surname>Chen</surname><given-names>T</given-names></name></person-group><article-title>Role of CAR and PXR in xenobiotic sensing and metabolism</article-title><source>Expert Opin Drug Metab Toxicol</source><year>2012</year><volume>8</volume><issue>7</issue><fpage>803</fpage><lpage>817</lpage><pub-id pub-id-type="doi">10.1517/17425255.2012.685237</pub-id><pub-id pub-id-type="pmid">22554043</pub-id><pub-id pub-id-type="pmcid">PMC3593589</pub-id></element-citation><mixed-citation id="mc-CR17" publication-type="journal">Wang YM, Ong SS, Chai SC, Chen T. Role of CAR and PXR in xenobiotic sensing and metabolism. Expert Opin Drug Metab Toxicol. 2012;8(7):803&#8211;17.<pub-id pub-id-type="pmid">22554043</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1517/17425255.2012.685237</pub-id><pub-id pub-id-type="pmcid">PMC3593589</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR18"><label>18.</label><citation-alternatives><element-citation id="ec-CR18" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lutz</surname><given-names>JD</given-names></name><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Wang</surname><given-names>L</given-names></name><name name-style="western"><surname>Song</surname><given-names>Q</given-names></name><name name-style="western"><surname>Ling</surname><given-names>J</given-names></name><name name-style="western"><surname>Massetto</surname><given-names>B</given-names></name><etal/></person-group><article-title>Cytochrome P450 3A Induction predicts P-glycoprotein induction; Part 1: Establishing induction relationships using ascending dose rifampin</article-title><source>Clin Pharmacol Ther</source><year>2018</year><volume>104</volume><issue>6</issue><fpage>1182</fpage><lpage>1190</lpage><pub-id pub-id-type="doi">10.1002/cpt.1073</pub-id><pub-id pub-id-type="pmid">29569723</pub-id><pub-id pub-id-type="pmcid">PMC6282691</pub-id></element-citation><mixed-citation id="mc-CR18" publication-type="journal">Lutz JD, Kirby BJ, Wang L, Song Q, Ling J, Massetto B, et al. Cytochrome P450 3A Induction predicts P-glycoprotein induction; Part 1: Establishing induction relationships using ascending dose rifampin. Clin Pharmacol Ther. 2018;104(6):1182&#8211;90.<pub-id pub-id-type="pmid">29569723</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1073</pub-id><pub-id pub-id-type="pmcid">PMC6282691</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR19"><label>19.</label><citation-alternatives><element-citation id="ec-CR19" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mizuno</surname><given-names>N</given-names></name><name name-style="western"><surname>Sugiyama</surname><given-names>Y</given-names></name></person-group><article-title>Drug transporters: their role and importance in the selection and development of new drugs</article-title><source>Drug Metab Pharmacokinet</source><year>2002</year><volume>17</volume><issue>2</issue><fpage>93</fpage><lpage>108</lpage><pub-id pub-id-type="doi">10.2133/dmpk.17.93</pub-id><pub-id pub-id-type="pmid">15618657</pub-id></element-citation><mixed-citation id="mc-CR19" publication-type="journal">Mizuno N, Sugiyama Y. Drug transporters: their role and importance in the selection and development of new drugs. Drug Metab Pharmacokinet. 2002;17(2):93&#8211;108.<pub-id pub-id-type="pmid">15618657</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2133/dmpk.17.93</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR20"><label>20.</label><citation-alternatives><element-citation id="ec-CR20" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Varma</surname><given-names>MV</given-names></name><name name-style="western"><surname>Ashokraj</surname><given-names>Y</given-names></name><name name-style="western"><surname>Dey</surname><given-names>CS</given-names></name><name name-style="western"><surname>Panchagnula</surname><given-names>R</given-names></name></person-group><article-title>P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement</article-title><source>Pharmacol Res</source><year>2003</year><volume>48</volume><issue>4</issue><fpage>347</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1016/S1043-6618(03)00158-0</pub-id><pub-id pub-id-type="pmid">12902205</pub-id></element-citation><mixed-citation id="mc-CR20" publication-type="journal">Varma MV, Ashokraj Y, Dey CS, Panchagnula R. P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacol Res. 2003;48(4):347&#8211;59.<pub-id pub-id-type="pmid">12902205</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s1043-6618(03)00158-0</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR21"><label>21.</label><citation-alternatives><element-citation id="ec-CR21" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kunta</surname><given-names>JR</given-names></name><name name-style="western"><surname>Sinko</surname><given-names>PJ</given-names></name></person-group><article-title>Intestinal drug transporters: in vivo function and clinical importance</article-title><source>Curr Drug Metab</source><year>2004</year><volume>5</volume><issue>1</issue><fpage>109</fpage><lpage>124</lpage><pub-id pub-id-type="doi">10.2174/1389200043489144</pub-id><pub-id pub-id-type="pmid">14965254</pub-id></element-citation><mixed-citation id="mc-CR21" publication-type="journal">Kunta JR, Sinko PJ. Intestinal drug transporters: in vivo function and clinical importance. Curr Drug Metab. 2004;5(1):109&#8211;24.<pub-id pub-id-type="pmid">14965254</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2174/1389200043489144</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR22"><label>22.</label><citation-alternatives><element-citation id="ec-CR22" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Giacomini</surname><given-names>KM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Tweedie</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Benet</surname><given-names>LZ</given-names></name><name name-style="western"><surname>Brouwer</surname><given-names>KL</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X</given-names></name><etal/></person-group><article-title>Membrane transporters in drug development</article-title><source>Nat Rev Drug Discov</source><year>2010</year><volume>9</volume><issue>3</issue><fpage>215</fpage><lpage>236</lpage><pub-id pub-id-type="doi">10.1038/nrd3028</pub-id><pub-id pub-id-type="pmid">20190787</pub-id><pub-id pub-id-type="pmcid">PMC3326076</pub-id></element-citation><mixed-citation id="mc-CR22" publication-type="journal">Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215&#8211;36.<pub-id pub-id-type="pmid">20190787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nrd3028</pub-id><pub-id pub-id-type="pmcid">PMC3326076</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR23"><label>23.</label><citation-alternatives><element-citation id="ec-CR23" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tweedie</surname><given-names>D</given-names></name><name name-style="western"><surname>Polli</surname><given-names>JW</given-names></name><name name-style="western"><surname>Berglund</surname><given-names>EG</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name><name name-style="western"><surname>Poirier</surname><given-names>A</given-names></name><etal/></person-group><article-title>Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium</article-title><source>Clin Pharmacol Ther</source><year>2013</year><volume>94</volume><issue>1</issue><fpage>113</fpage><lpage>125</lpage><pub-id pub-id-type="doi">10.1038/clpt.2013.77</pub-id><pub-id pub-id-type="pmid">23588318</pub-id></element-citation><mixed-citation id="mc-CR23" publication-type="journal">Tweedie D, Polli JW, Berglund EG, Huang SM, Zhang L, Poirier A, et al. Transporter studies in drug development: experience to date and follow-up on decision trees from the International Transporter Consortium. Clin Pharmacol Ther. 2013;94(1):113&#8211;25.<pub-id pub-id-type="pmid">23588318</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2013.77</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">EMA. Guideline on the investigation of drug interactions. 2012. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/07/WC500129606.pdf</ext-link>. Accessed 29 Dec 2022.</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">FDA. Drug interaction studies&#8212;study design, data analysis, implications for dosing, and labeling recommendations. Draft guidance. 2012. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf">http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm292362.pdf</ext-link>. Accessed 22 Mar 2023.</mixed-citation></ref><ref id="CR26"><label>26.</label><mixed-citation publication-type="other">FDA. Drug Development and Drug Interactions|Table of Substrates, Inhibitors and Inducers 2023. <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers">https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers</ext-link>. Accessed 12 May 2023.</mixed-citation></ref><ref id="CR27"><label>27.</label><citation-alternatives><element-citation id="ec-CR27" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>JE</given-names></name><name name-style="western"><surname>Bossuyt</surname><given-names>PM</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>TC</given-names></name><name name-style="western"><surname>Mulrow</surname><given-names>CD</given-names></name><etal/></person-group><article-title>The PRISMA 2020 statement: an updated guideline for reporting systematic reviews</article-title><source>BMJ</source><year>2021</year><volume>372</volume><fpage>n71</fpage><pub-id pub-id-type="doi">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></element-citation><mixed-citation id="mc-CR27" publication-type="journal">Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.<pub-id pub-id-type="pmid">33782057</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.n71</pub-id><pub-id pub-id-type="pmcid">PMC8005924</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR28"><label>28.</label><citation-alternatives><element-citation id="ec-CR28" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McGowan</surname><given-names>J</given-names></name><name name-style="western"><surname>Sampson</surname><given-names>M</given-names></name><name name-style="western"><surname>Salzwedel</surname><given-names>DM</given-names></name><name name-style="western"><surname>Cogo</surname><given-names>E</given-names></name><name name-style="western"><surname>Foerster</surname><given-names>V</given-names></name><name name-style="western"><surname>Lefebvre</surname><given-names>C</given-names></name></person-group><article-title>PRESS peer review of electronic search strategies: 2015 guideline statement</article-title><source>J Clin Epidemiol</source><year>2016</year><volume>75</volume><fpage>40</fpage><lpage>46</lpage><pub-id pub-id-type="doi">10.1016/j.jclinepi.2016.01.021</pub-id><pub-id pub-id-type="pmid">27005575</pub-id></element-citation><mixed-citation id="mc-CR28" publication-type="journal">McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS peer review of electronic search strategies: 2015 guideline statement. J Clin Epidemiol. 2016;75:40&#8211;6.<pub-id pub-id-type="pmid">27005575</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jclinepi.2016.01.021</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR29"><label>29.</label><citation-alternatives><element-citation id="ec-CR29" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouzzani</surname><given-names>M</given-names></name><name name-style="western"><surname>Hammady</surname><given-names>H</given-names></name><name name-style="western"><surname>Fedorowicz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Elmagarmid</surname><given-names>A</given-names></name></person-group><article-title>Rayyan&#8212;a web and mobile app for systematic reviews</article-title><source>Syst Rev</source><year>2016</year><volume>5</volume><issue>1</issue><fpage>210</fpage><pub-id pub-id-type="doi">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmid">27919275</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id></element-citation><mixed-citation id="mc-CR29" publication-type="journal">Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan&#8212;a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210.<pub-id pub-id-type="pmid">27919275</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s13643-016-0384-4</pub-id><pub-id pub-id-type="pmcid">PMC5139140</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR30"><label>30.</label><citation-alternatives><element-citation id="ec-CR30" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>JA</given-names></name><name name-style="western"><surname>Hern&#225;n</surname><given-names>MA</given-names></name><name name-style="western"><surname>Reeves</surname><given-names>BC</given-names></name><name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Berkman</surname><given-names>ND</given-names></name><name name-style="western"><surname>Viswanathan</surname><given-names>M</given-names></name><etal/></person-group><article-title>ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions</article-title><source>BMJ</source><year>2016</year><volume>355</volume><fpage>i4919</fpage><pub-id pub-id-type="doi">10.1136/bmj.i4919</pub-id><pub-id pub-id-type="pmid">27733354</pub-id><pub-id pub-id-type="pmcid">PMC5062054</pub-id></element-citation><mixed-citation id="mc-CR30" publication-type="journal">Sterne JA, Hern&#225;n MA, Reeves BC, Savovi&#263; J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016;355: i4919.<pub-id pub-id-type="pmid">27733354</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.i4919</pub-id><pub-id pub-id-type="pmcid">PMC5062054</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR31"><label>31.</label><citation-alternatives><element-citation id="ec-CR31" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>JAC</given-names></name><name name-style="western"><surname>Savovi&#263;</surname><given-names>J</given-names></name><name name-style="western"><surname>Page</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Elbers</surname><given-names>RG</given-names></name><name name-style="western"><surname>Blencowe</surname><given-names>NS</given-names></name><name name-style="western"><surname>Boutron</surname><given-names>I</given-names></name><etal/></person-group><article-title>RoB 2: a revised tool for assessing risk of bias in randomised trials</article-title><source>BMJ</source><year>2019</year><volume>366</volume><fpage>l4898</fpage><pub-id pub-id-type="doi">10.1136/bmj.l4898</pub-id><pub-id pub-id-type="pmid">31462531</pub-id></element-citation><mixed-citation id="mc-CR31" publication-type="journal">Sterne JAC, Savovi&#263; J, Page MJ, Elbers RG, Blencowe NS, Boutron I, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366: l4898.<pub-id pub-id-type="pmid">31462531</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1136/bmj.l4898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR32"><label>32.</label><citation-alternatives><element-citation id="ec-CR32" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kanji</surname><given-names>S</given-names></name><name name-style="western"><surname>Hayes</surname><given-names>M</given-names></name><name name-style="western"><surname>Ling</surname><given-names>A</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Chant</surname><given-names>C</given-names></name><name name-style="western"><surname>Edwards</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Reporting Guidelines for clinical pharmacokinetic studies: the ClinPK Statement</article-title><source>Clin Pharmacokinet</source><year>2015</year><volume>54</volume><issue>7</issue><fpage>783</fpage><lpage>795</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0236-8</pub-id><pub-id pub-id-type="pmid">25637173</pub-id></element-citation><mixed-citation id="mc-CR32" publication-type="journal">Kanji S, Hayes M, Ling A, Shamseer L, Chant C, Edwards DJ, et al. Reporting Guidelines for clinical pharmacokinetic studies: the ClinPK Statement. Clin Pharmacokinet. 2015;54(7):783&#8211;95.<pub-id pub-id-type="pmid">25637173</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0236-8</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR33"><label>33.</label><citation-alternatives><element-citation id="ec-CR33" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uno</surname><given-names>T</given-names></name><name name-style="western"><surname>Shimizu</surname><given-names>M</given-names></name><name name-style="western"><surname>Sugawara</surname><given-names>K</given-names></name><name name-style="western"><surname>Tateishi</surname><given-names>T</given-names></name></person-group><article-title>Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine</article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><issue>11</issue><fpage>1875</fpage><lpage>1879</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.011023</pub-id><pub-id pub-id-type="pmid">16928786</pub-id></element-citation><mixed-citation id="mc-CR33" publication-type="journal">Uno T, Shimizu M, Sugawara K, Tateishi T. Lack of dose-dependent effects of itraconazole on the pharmacokinetic interaction with fexofenadine. Drug Metab Dispos. 2006;34(11):1875&#8211;9.<pub-id pub-id-type="pmid">16928786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.011023</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR34"><label>34.</label><citation-alternatives><element-citation id="ec-CR34" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boyd</surname><given-names>RA</given-names></name><name name-style="western"><surname>Stern</surname><given-names>RH</given-names></name><name name-style="western"><surname>Stewart</surname><given-names>BH</given-names></name><name name-style="western"><surname>Wu</surname><given-names>X</given-names></name><name name-style="western"><surname>Reyner</surname><given-names>EL</given-names></name><name name-style="western"><surname>Zegarac</surname><given-names>EA</given-names></name><etal/></person-group><article-title>Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion</article-title><source>J Clin Pharmacol</source><year>2000</year><volume>40</volume><issue>1</issue><fpage>91</fpage><lpage>98</lpage><pub-id pub-id-type="pmid">10631627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912700022008612</pub-id></element-citation><mixed-citation id="mc-CR34" publication-type="journal">Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, et al. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. J Clin Pharmacol. 2000;40(1):91&#8211;8.<pub-id pub-id-type="pmid">10631627</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/00912700022008612</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR35"><label>35.</label><citation-alternatives><element-citation id="ec-CR35" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elsby</surname><given-names>R</given-names></name><name name-style="western"><surname>Gillen</surname><given-names>M</given-names></name><name name-style="western"><surname>Butters</surname><given-names>C</given-names></name><name name-style="western"><surname>Imisson</surname><given-names>G</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Smith</surname><given-names>V</given-names></name><etal/></person-group><article-title>The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug&#8211;drug interactions: a case study for AZD5672</article-title><source>Drug Metab Dispos</source><year>2011</year><volume>39</volume><issue>2</issue><fpage>275</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1124/dmd.110.035881</pub-id><pub-id pub-id-type="pmid">21075975</pub-id></element-citation><mixed-citation id="mc-CR35" publication-type="journal">Elsby R, Gillen M, Butters C, Imisson G, Sharma P, Smith V, et al. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug&#8211;drug interactions: a case study for AZD5672. Drug Metab Dispos. 2011;39(2):275&#8211;82.<pub-id pub-id-type="pmid">21075975</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.110.035881</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR36"><label>36.</label><citation-alternatives><element-citation id="ec-CR36" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edwards</surname><given-names>JE</given-names></name><name name-style="western"><surname>Eliot</surname><given-names>L</given-names></name><name name-style="western"><surname>Parkinson</surname><given-names>A</given-names></name><name name-style="western"><surname>Karan</surname><given-names>S</given-names></name><name name-style="western"><surname>MacConell</surname><given-names>L</given-names></name></person-group><article-title>Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects</article-title><source>Adv Ther</source><year>2017</year><volume>34</volume><issue>9</issue><fpage>2120</fpage><lpage>2138</lpage><pub-id pub-id-type="doi">10.1007/s12325-017-0601-0</pub-id><pub-id pub-id-type="pmid">28808886</pub-id><pub-id pub-id-type="pmcid">PMC5599467</pub-id></element-citation><mixed-citation id="mc-CR36" publication-type="journal">Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of pharmacokinetic interactions between obeticholic acid and caffeine, midazolam, warfarin, dextromethorphan, omeprazole, rosuvastatin, and digoxin in phase 1 studies in healthy subjects. Adv Ther. 2017;34(9):2120&#8211;38.<pub-id pub-id-type="pmid">28808886</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s12325-017-0601-0</pub-id><pub-id pub-id-type="pmcid">PMC5599467</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR37"><label>37.</label><citation-alternatives><element-citation id="ec-CR37" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Akamine</surname><given-names>Y</given-names></name><name name-style="western"><surname>Miura</surname><given-names>M</given-names></name><name name-style="western"><surname>Yasui-Furukori</surname><given-names>N</given-names></name><name name-style="western"><surname>Ieiri</surname><given-names>I</given-names></name><name name-style="western"><surname>Uno</surname><given-names>T</given-names></name></person-group><article-title>Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers</article-title><source>J Clin Pharm Ther</source><year>2015</year><volume>40</volume><issue>1</issue><fpage>98</fpage><lpage>103</lpage><pub-id pub-id-type="doi">10.1111/jcpt.12213</pub-id><pub-id pub-id-type="pmid">25263393</pub-id></element-citation><mixed-citation id="mc-CR37" publication-type="journal">Akamine Y, Miura M, Yasui-Furukori N, Ieiri I, Uno T. Effects of multiple-dose rifampicin 450 mg on the pharmacokinetics of fexofenadine enantiomers in Japanese volunteers. J Clin Pharm Ther. 2015;40(1):98&#8211;103.<pub-id pub-id-type="pmid">25263393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/jcpt.12213</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR38"><label>38.</label><citation-alternatives><element-citation id="ec-CR38" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Bedynek</surname><given-names>PS</given-names></name><name name-style="western"><surname>Walker</surname><given-names>A</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>D</given-names></name><name name-style="western"><surname>Hoffer</surname><given-names>C</given-names></name></person-group><article-title>Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities</article-title><source>Clin Pharmacol Ther</source><year>2008</year><volume>84</volume><issue>4</issue><fpage>506</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.102</pub-id><pub-id pub-id-type="pmid">19238656</pub-id><pub-id pub-id-type="pmcid">PMC3583338</pub-id></element-citation><mixed-citation id="mc-CR38" publication-type="journal">Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther. 2008;84(4):506&#8211;12.<pub-id pub-id-type="pmid">19238656</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.102</pub-id><pub-id pub-id-type="pmcid">PMC3583338</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR39"><label>39.</label><citation-alternatives><element-citation id="ec-CR39" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fenner</surname><given-names>KS</given-names></name><name name-style="western"><surname>Troutman</surname><given-names>MD</given-names></name><name name-style="western"><surname>Kempshall</surname><given-names>S</given-names></name><name name-style="western"><surname>Cook</surname><given-names>JA</given-names></name><name name-style="western"><surname>Ware</surname><given-names>JA</given-names></name><name name-style="western"><surname>Smith</surname><given-names>DA</given-names></name><etal/></person-group><article-title>Drug&#8211;drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug</article-title><source>Clin Pharmacol Ther</source><year>2009</year><volume>85</volume><issue>2</issue><fpage>173</fpage><lpage>181</lpage><pub-id pub-id-type="doi">10.1038/clpt.2008.195</pub-id><pub-id pub-id-type="pmid">18987624</pub-id></element-citation><mixed-citation id="mc-CR39" publication-type="journal">Fenner KS, Troutman MD, Kempshall S, Cook JA, Ware JA, Smith DA, et al. Drug&#8211;drug interactions mediated through P-glycoprotein: clinical relevance and in vitro-in vivo correlation using digoxin as a probe drug. Clin Pharmacol Ther. 2009;85(2):173&#8211;81.<pub-id pub-id-type="pmid">18987624</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2008.195</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR40"><label>40.</label><citation-alternatives><element-citation id="ec-CR40" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Umeyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Fujioka</surname><given-names>Y</given-names></name><name name-style="western"><surname>Okuda</surname><given-names>T</given-names></name></person-group><article-title>Clarification of P-glycoprotein inhibition-related drug&#8211;drug interaction risks based on a literature search of the clinical information</article-title><source>Xenobiotica</source><year>2014</year><volume>44</volume><issue>12</issue><fpage>1135</fpage><lpage>1144</lpage><pub-id pub-id-type="doi">10.3109/00498254.2014.928958</pub-id><pub-id pub-id-type="pmid">24937160</pub-id></element-citation><mixed-citation id="mc-CR40" publication-type="journal">Umeyama Y, Fujioka Y, Okuda T. Clarification of P-glycoprotein inhibition-related drug&#8211;drug interaction risks based on a literature search of the clinical information. Xenobiotica. 2014;44(12):1135&#8211;44.<pub-id pub-id-type="pmid">24937160</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3109/00498254.2014.928958</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR41"><label>41.</label><citation-alternatives><element-citation id="ec-CR41" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Elmeliegy</surname><given-names>M</given-names></name><name name-style="western"><surname>Vourvahis</surname><given-names>M</given-names></name><name name-style="western"><surname>Guo</surname><given-names>C</given-names></name><name name-style="western"><surname>Wang</surname><given-names>DD</given-names></name></person-group><article-title>Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug&#8211;drug interaction studies</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><issue>6</issue><fpage>699</fpage><lpage>714</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00867-1</pub-id><pub-id pub-id-type="pmid">32052379</pub-id><pub-id pub-id-type="pmcid">PMC7292822</pub-id></element-citation><mixed-citation id="mc-CR41" publication-type="journal">Elmeliegy M, Vourvahis M, Guo C, Wang DD. Effect of P-glycoprotein (P-gp) inducers on exposure of P-gp substrates: review of clinical drug&#8211;drug interaction studies. Clin Pharmacokinet. 2020;59(6):699&#8211;714.<pub-id pub-id-type="pmid">32052379</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-020-00867-1</pub-id><pub-id pub-id-type="pmcid">PMC7292822</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR42"><label>42.</label><citation-alternatives><element-citation id="ec-CR42" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hartter</surname><given-names>S</given-names></name><name name-style="western"><surname>Koenen-Bergmann</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name><name name-style="western"><surname>Nehmiz</surname><given-names>G</given-names></name><name name-style="western"><surname>Lemke</surname><given-names>U</given-names></name><name name-style="western"><surname>Timmer</surname><given-names>W</given-names></name><etal/></person-group><article-title>Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin</article-title><source>Br J Clin Pharmacol</source><year>2012</year><volume>74</volume><issue>3</issue><fpage>490</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/j.1365-2125.2012.04218.x</pub-id><pub-id pub-id-type="pmid">22348256</pub-id><pub-id pub-id-type="pmcid">PMC3477350</pub-id></element-citation><mixed-citation id="mc-CR42" publication-type="journal">Hartter S, Koenen-Bergmann M, Sharma A, Nehmiz G, Lemke U, Timmer W, et al. Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. Br J Clin Pharmacol. 2012;74(3):490&#8211;500.<pub-id pub-id-type="pmid">22348256</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/j.1365-2125.2012.04218.x</pub-id><pub-id pub-id-type="pmcid">PMC3477350</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR43"><label>43.</label><citation-alternatives><element-citation id="ec-CR43" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kusuhara</surname><given-names>H</given-names></name><name name-style="western"><surname>Miura</surname><given-names>M</given-names></name><name name-style="western"><surname>Yasui-Furukori</surname><given-names>N</given-names></name><name name-style="western"><surname>Yoshida</surname><given-names>K</given-names></name><name name-style="western"><surname>Akamine</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yokochi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects</article-title><source>Drug Metab Dispos</source><year>2013</year><volume>41</volume><issue>1</issue><fpage>206</fpage><lpage>213</lpage><pub-id pub-id-type="doi">10.1124/dmd.112.048330</pub-id><pub-id pub-id-type="pmid">23115085</pub-id></element-citation><mixed-citation id="mc-CR43" publication-type="journal">Kusuhara H, Miura M, Yasui-Furukori N, Yoshida K, Akamine Y, Yokochi M, et al. Effect of coadministration of single and multiple doses of rifampicin on the pharmacokinetics of fexofenadine enantiomers in healthy subjects. Drug Metab Dispos. 2013;41(1):206&#8211;13.<pub-id pub-id-type="pmid">23115085</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.112.048330</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR44"><label>44.</label><citation-alternatives><element-citation id="ec-CR44" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Joseph</surname><given-names>DM</given-names></name><name name-style="western"><surname>Shirley</surname><given-names>MT</given-names></name><name name-style="western"><surname>Joseph</surname><given-names>SBJ</given-names></name><name name-style="western"><surname>Trivedi</surname><given-names>M</given-names></name><name name-style="western"><surname>Keola</surname><given-names>KB</given-names></name><name name-style="western"><surname>Anne</surname><given-names>NN</given-names></name></person-group><article-title>Evaluation of in vivo P-glycoprotein phenotyping probes</article-title><source>Clin Pharmacokinet</source><year>2010</year><volume>49</volume><fpage>223</fpage><lpage>237</lpage><pub-id pub-id-type="doi">10.2165/11318000-000000000-00000</pub-id><pub-id pub-id-type="pmid">20214407</pub-id></element-citation><mixed-citation id="mc-CR44" publication-type="journal">Joseph DM, Shirley MT, Joseph SBJ, Trivedi M, Keola KB, Anne NN. Evaluation of in vivo P-glycoprotein phenotyping probes. Clin Pharmacokinet. 2010;49:223&#8211;37.<pub-id pub-id-type="pmid">20214407</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2165/11318000-000000000-00000</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR45"><label>45.</label><citation-alternatives><element-citation id="ec-CR45" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukushima</surname><given-names>K</given-names></name><name name-style="western"><surname>Kobuchi</surname><given-names>S</given-names></name><name name-style="western"><surname>Mizuhara</surname><given-names>K</given-names></name><name name-style="western"><surname>Aoyama</surname><given-names>H</given-names></name><name name-style="western"><surname>Takada</surname><given-names>K</given-names></name><name name-style="western"><surname>Sugioka</surname><given-names>N</given-names></name></person-group><article-title>Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A</article-title><source>J Pharm Sci</source><year>2013</year><volume>102</volume><issue>6</issue><fpage>2044</fpage><lpage>2055</lpage><pub-id pub-id-type="doi">10.1002/jps.23545</pub-id><pub-id pub-id-type="pmid">23589366</pub-id></element-citation><mixed-citation id="mc-CR45" publication-type="journal">Fukushima K, Kobuchi S, Mizuhara K, Aoyama H, Takada K, Sugioka N. Time-dependent interaction of ritonavir in chronic use: the power balance between inhibition and induction of P-glycoprotein and cytochrome P450 3A. J Pharm Sci. 2013;102(6):2044&#8211;55.<pub-id pub-id-type="pmid">23589366</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jps.23545</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR46"><label>46.</label><citation-alternatives><element-citation id="ec-CR46" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Loos</surname><given-names>NHC</given-names></name><name name-style="western"><surname>Beijnen</surname><given-names>JH</given-names></name><name name-style="western"><surname>Schinkel</surname><given-names>AH</given-names></name></person-group><article-title>The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>162</volume><fpage>114636</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.114636</pub-id><pub-id pub-id-type="pmid">37004323</pub-id><pub-id pub-id-type="pmcid">PMC10065864</pub-id></element-citation><mixed-citation id="mc-CR46" publication-type="journal">Loos NHC, Beijnen JH, Schinkel AH. The inhibitory and inducing effects of ritonavir on hepatic and intestinal CYP3A and other drug-handling proteins. Biomed Pharmacother. 2023;162: 114636.<pub-id pub-id-type="pmid">37004323</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.biopha.2023.114636</pub-id><pub-id pub-id-type="pmcid">PMC10065864</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR47"><label>47.</label><citation-alternatives><element-citation id="ec-CR47" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hennessy</surname><given-names>M</given-names></name><name name-style="western"><surname>Kelleher</surname><given-names>D</given-names></name><name name-style="western"><surname>Spiers</surname><given-names>JP</given-names></name><name name-style="western"><surname>Barry</surname><given-names>M</given-names></name><name name-style="western"><surname>Kavanagh</surname><given-names>P</given-names></name><name name-style="western"><surname>Back</surname><given-names>D</given-names></name><etal/></person-group><article-title>St Johns wort increases expression of P-glycoprotein: implications for drug interactions</article-title><source>Br J Clin Pharmacol</source><year>2002</year><volume>53</volume><issue>1</issue><fpage>75</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1046/j.0306-5251.2001.01516.x</pub-id><pub-id pub-id-type="pmid">11849198</pub-id><pub-id pub-id-type="pmcid">PMC1874544</pub-id></element-citation><mixed-citation id="mc-CR47" publication-type="journal">Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, et al. St Johns wort increases expression of P-glycoprotein: implications for drug interactions. Br J Clin Pharmacol. 2002;53(1):75&#8211;82.<pub-id pub-id-type="pmid">11849198</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1046/j.0306-5251.2001.01516.x</pub-id><pub-id pub-id-type="pmcid">PMC1874544</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR48"><label>48.</label><citation-alternatives><element-citation id="ec-CR48" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tian</surname><given-names>R</given-names></name><name name-style="western"><surname>Koyabu</surname><given-names>N</given-names></name><name name-style="western"><surname>Morimoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Shoyama</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ohtani</surname><given-names>H</given-names></name><name name-style="western"><surname>Sawada</surname><given-names>Y</given-names></name></person-group><article-title>Functional induction and de-induction of P-glycoprotein by St. John's wort and its ingredients in a human colon adenocarcinoma cell line</article-title><source>Drug Metab Dispos</source><year>2005</year><volume>33</volume><issue>4</issue><fpage>547</fpage><lpage>554</lpage><pub-id pub-id-type="doi">10.1124/dmd.104.002485</pub-id><pub-id pub-id-type="pmid">15640377</pub-id></element-citation><mixed-citation id="mc-CR48" publication-type="journal">Tian R, Koyabu N, Morimoto S, Shoyama Y, Ohtani H, Sawada Y. Functional induction and de-induction of P-glycoprotein by St. John&#8217;s wort and its ingredients in a human colon adenocarcinoma cell line. Drug Metab Dispos. 2005;33(4):547&#8211;54.<pub-id pub-id-type="pmid">15640377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.104.002485</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR49"><label>49.</label><citation-alternatives><element-citation id="ec-CR49" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Back</surname><given-names>D</given-names></name><name name-style="western"><surname>Sekar</surname><given-names>V</given-names></name><name name-style="western"><surname>Hoetelmans</surname><given-names>RM</given-names></name></person-group><article-title>Darunavir: pharmacokinetics and drug interactions</article-title><source>Antivir Ther</source><year>2008</year><volume>13</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1177/135965350801300101</pub-id><pub-id pub-id-type="pmid">18389894</pub-id></element-citation><mixed-citation id="mc-CR49" publication-type="journal">Back D, Sekar V, Hoetelmans RM. Darunavir: pharmacokinetics and drug interactions. Antivir Ther. 2008;13(1):1&#8211;13.<pub-id pub-id-type="pmid">18389894</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR50"><label>50.</label><citation-alternatives><element-citation id="ec-CR50" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wolking</surname><given-names>S</given-names></name><name name-style="western"><surname>Schaeffeler</surname><given-names>E</given-names></name><name name-style="western"><surname>Lerche</surname><given-names>H</given-names></name><name name-style="western"><surname>Schwab</surname><given-names>M</given-names></name><name name-style="western"><surname>Nies</surname><given-names>AT</given-names></name></person-group><article-title>Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature</article-title><source>Clin Pharmacokinet</source><year>2015</year><volume>54</volume><issue>7</issue><fpage>709</fpage><lpage>735</lpage><pub-id pub-id-type="doi">10.1007/s40262-015-0267-1</pub-id><pub-id pub-id-type="pmid">25860377</pub-id></element-citation><mixed-citation id="mc-CR50" publication-type="journal">Wolking S, Schaeffeler E, Lerche H, Schwab M, Nies AT. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet. 2015;54(7):709&#8211;35.<pub-id pub-id-type="pmid">25860377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-015-0267-1</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR51"><label>51.</label><citation-alternatives><element-citation id="ec-CR51" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tannenbaum</surname><given-names>C</given-names></name><name name-style="western"><surname>Sheehan</surname><given-names>NL</given-names></name></person-group><article-title>Understanding and preventing drug&#8211;drug and drug&#8211;gene interactions</article-title><source>Expert Rev Clin Pharmacol</source><year>2014</year><volume>7</volume><issue>4</issue><fpage>533</fpage><lpage>544</lpage><pub-id pub-id-type="doi">10.1586/17512433.2014.910111</pub-id><pub-id pub-id-type="pmid">24745854</pub-id><pub-id pub-id-type="pmcid">PMC4894065</pub-id></element-citation><mixed-citation id="mc-CR51" publication-type="journal">Tannenbaum C, Sheehan NL. Understanding and preventing drug&#8211;drug and drug&#8211;gene interactions. Expert Rev Clin Pharmacol. 2014;7(4):533&#8211;44.<pub-id pub-id-type="pmid">24745854</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1586/17512433.2014.910111</pub-id><pub-id pub-id-type="pmcid">PMC4894065</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR52"><label>52.</label><citation-alternatives><element-citation id="ec-CR52" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mendell</surname><given-names>J</given-names></name><name name-style="western"><surname>Zahir</surname><given-names>H</given-names></name><name name-style="western"><surname>Matsushima</surname><given-names>N</given-names></name><name name-style="western"><surname>Noveck</surname><given-names>R</given-names></name><name name-style="western"><surname>Lee</surname><given-names>F</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S</given-names></name><etal/></person-group><article-title>Drug&#8211;drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor</article-title><source>Am J Cardiovasc Drugs Drugs Devices Other Interv.</source><year>2013</year><volume>13</volume><issue>5</issue><fpage>331</fpage><lpage>342</lpage><pub-id pub-id-type="doi">10.1007/s40256-013-0029-0</pub-id><pub-id pub-id-type="pmcid">PMC3781304</pub-id><pub-id pub-id-type="pmid">23784266</pub-id></element-citation><mixed-citation id="mc-CR52" publication-type="journal">Mendell J, Zahir H, Matsushima N, Noveck R, Lee F, Chen S, et al. Drug&#8211;drug interaction studies of cardiovascular drugs involving P-glycoprotein, an efflux transporter, on the pharmacokinetics of edoxaban, an oral factor Xa inhibitor. Am J Cardiovasc Drugs Drugs Devices Other Interv. 2013;13(5):331&#8211;42.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40256-013-0029-0</pub-id><pub-id pub-id-type="pmcid">PMC3781304</pub-id><pub-id pub-id-type="pmid">23784266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR53"><label>53.</label><citation-alternatives><element-citation id="ec-CR53" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fukumura</surname><given-names>K</given-names></name><name name-style="western"><surname>Kawaguchi</surname><given-names>N</given-names></name><name name-style="western"><surname>Ishibashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Kubota</surname><given-names>R</given-names></name><name name-style="western"><surname>Tada</surname><given-names>Y</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>E</given-names></name></person-group><article-title>Clinical drug&#8211;drug interaction studies to evaluate the effects of a P-glycoprotein inhibitor, CYP3A inhibitors, and a CYP3A inducer on the pharmacokinetics of naldemedine in healthy subjects</article-title><source>Clin Drug Investig</source><year>2020</year><volume>40</volume><issue>6</issue><fpage>529</fpage><lpage>540</lpage><pub-id pub-id-type="doi">10.1007/s40261-020-00902-w</pub-id><pub-id pub-id-type="pmid">32323104</pub-id><pub-id pub-id-type="pmcid">PMC7242238</pub-id></element-citation><mixed-citation id="mc-CR53" publication-type="journal">Fukumura K, Kawaguchi N, Ishibashi T, Kubota R, Tada Y, Ogura E. Clinical drug&#8211;drug interaction studies to evaluate the effects of a P-glycoprotein inhibitor, CYP3A inhibitors, and a CYP3A inducer on the pharmacokinetics of naldemedine in healthy subjects. Clin Drug Investig. 2020;40(6):529&#8211;40.<pub-id pub-id-type="pmid">32323104</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40261-020-00902-w</pub-id><pub-id pub-id-type="pmcid">PMC7242238</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR54"><label>54.</label><citation-alternatives><element-citation id="ec-CR54" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lu</surname><given-names>J</given-names></name><name name-style="western"><surname>Yao</surname><given-names>B</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Huang</surname><given-names>S</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><etal/></person-group><article-title>P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats</article-title><source>Toxicol Appl Pharmacol</source><year>2021</year><volume>431</volume><fpage>115735</fpage><pub-id pub-id-type="doi">10.1016/j.taap.2021.115735</pub-id><pub-id pub-id-type="pmid">34610281</pub-id></element-citation><mixed-citation id="mc-CR54" publication-type="journal">Xu Y, Lu J, Yao B, Zhang Y, Huang S, Liu J, et al. P-glycoprotein mediates the pharmacokinetic interaction of olanzapine with fluoxetine in rats. Toxicol Appl Pharmacol. 2021;431: 115735.<pub-id pub-id-type="pmid">34610281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.taap.2021.115735</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR55"><label>55.</label><citation-alternatives><element-citation id="ec-CR55" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schwarz</surname><given-names>UI</given-names></name><name name-style="western"><surname>Gramatt&#233;</surname><given-names>T</given-names></name><name name-style="western"><surname>Krappweis</surname><given-names>J</given-names></name><name name-style="western"><surname>Oertel</surname><given-names>R</given-names></name><name name-style="western"><surname>Kirch</surname><given-names>W</given-names></name></person-group><article-title>P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans</article-title><source>Int J Clin Pharmacol Ther</source><year>2000</year><volume>38</volume><issue>4</issue><fpage>161</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.5414/CPP38161</pub-id><pub-id pub-id-type="pmid">10783825</pub-id></element-citation><mixed-citation id="mc-CR55" publication-type="journal">Schwarz UI, Gramatt&#233; T, Krappweis J, Oertel R, Kirch W. P-glycoprotein inhibitor erythromycin increases oral bioavailability of talinolol in humans. Int J Clin Pharmacol Ther. 2000;38(4):161&#8211;7.<pub-id pub-id-type="pmid">10783825</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.5414/cpp38161</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR56"><label>56.</label><citation-alternatives><element-citation id="ec-CR56" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eyal</surname><given-names>S</given-names></name><name name-style="western"><surname>Lamb</surname><given-names>JG</given-names></name><name name-style="western"><surname>Smith-Yockman</surname><given-names>M</given-names></name><name name-style="western"><surname>Yagen</surname><given-names>B</given-names></name><name name-style="western"><surname>Fibach</surname><given-names>E</given-names></name><name name-style="western"><surname>Altschuler</surname><given-names>Y</given-names></name><etal/></person-group><article-title>The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver</article-title><source>Br J Pharmacol</source><year>2006</year><volume>149</volume><issue>3</issue><fpage>250</fpage><lpage>260</lpage><pub-id pub-id-type="doi">10.1038/sj.bjp.0706830</pub-id><pub-id pub-id-type="pmid">16894351</pub-id><pub-id pub-id-type="pmcid">PMC2014277</pub-id></element-citation><mixed-citation id="mc-CR56" publication-type="journal">Eyal S, Lamb JG, Smith-Yockman M, Yagen B, Fibach E, Altschuler Y, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol. 2006;149(3):250&#8211;60.<pub-id pub-id-type="pmid">16894351</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/sj.bjp.0706830</pub-id><pub-id pub-id-type="pmcid">PMC2014277</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR57"><label>57.</label><citation-alternatives><element-citation id="ec-CR57" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiebe</surname><given-names>ST</given-names></name><name name-style="western"><surname>Giessmann</surname><given-names>T</given-names></name><name name-style="western"><surname>Hohl</surname><given-names>K</given-names></name><name name-style="western"><surname>Schmidt-Gerets</surname><given-names>S</given-names></name><name name-style="western"><surname>Hauel</surname><given-names>E</given-names></name><name name-style="western"><surname>Jambrecina</surname><given-names>A</given-names></name><etal/></person-group><article-title>Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine</article-title><source>Clin Pharmacokinet</source><year>2020</year><volume>59</volume><issue>12</issue><fpage>1627</fpage><lpage>1639</lpage><pub-id pub-id-type="doi">10.1007/s40262-020-00907-w</pub-id><pub-id pub-id-type="pmid">32504272</pub-id><pub-id pub-id-type="pmcid">PMC7716890</pub-id></element-citation><mixed-citation id="mc-CR57" publication-type="journal">Wiebe ST, Giessmann T, Hohl K, Schmidt-Gerets S, Hauel E, Jambrecina A, et al. Validation of a drug transporter probe cocktail using the prototypical inhibitors rifampin, probenecid, verapamil, and cimetidine. Clin Pharmacokinet. 2020;59(12):1627&#8211;39.<pub-id pub-id-type="pmid">32504272</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s40262-020-00907-w</pub-id><pub-id pub-id-type="pmcid">PMC7716890</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR58"><label>58.</label><citation-alternatives><element-citation id="ec-CR58" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kirby</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Collier</surname><given-names>AC</given-names></name><name name-style="western"><surname>Kharasch</surname><given-names>ED</given-names></name><name name-style="western"><surname>Whittington</surname><given-names>D</given-names></name><name name-style="western"><surname>Thummel</surname><given-names>KE</given-names></name><name name-style="western"><surname>Unadkat</surname><given-names>JD</given-names></name></person-group><article-title>Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion</article-title><source>Drug Metab Dispos</source><year>2012</year><volume>40</volume><issue>3</issue><fpage>610</fpage><lpage>616</lpage><pub-id pub-id-type="doi">10.1124/dmd.111.042705</pub-id><pub-id pub-id-type="pmid">22190694</pub-id><pub-id pub-id-type="pmcid">PMC3286266</pub-id></element-citation><mixed-citation id="mc-CR58" publication-type="journal">Kirby BJ, Collier AC, Kharasch ED, Whittington D, Thummel KE, Unadkat JD. Complex drug interactions of the HIV protease inhibitors 3: effect of simultaneous or staggered dosing of digoxin and ritonavir, nelfinavir, rifampin, or bupropion. Drug Metab Dispos. 2012;40(3):610&#8211;6.<pub-id pub-id-type="pmid">22190694</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.111.042705</pub-id><pub-id pub-id-type="pmcid">PMC3286266</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR59"><label>59.</label><citation-alternatives><element-citation id="ec-CR59" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tatosian</surname><given-names>DA</given-names></name><name name-style="western"><surname>Yee</surname><given-names>KL</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mostoller</surname><given-names>K</given-names></name><name name-style="western"><surname>Paul</surname><given-names>E</given-names></name><name name-style="western"><surname>Sutradhar</surname><given-names>S</given-names></name><etal/></person-group><article-title>A microdose cocktail to evaluate drug interactions in patients with renal impairment</article-title><source>Clin Pharmacol Ther</source><year>2021</year><volume>109</volume><issue>2</issue><fpage>403</fpage><lpage>415</lpage><pub-id pub-id-type="doi">10.1002/cpt.1998</pub-id><pub-id pub-id-type="pmid">32705692</pub-id></element-citation><mixed-citation id="mc-CR59" publication-type="journal">Tatosian DA, Yee KL, Zhang Z, Mostoller K, Paul E, Sutradhar S, et al. A microdose cocktail to evaluate drug interactions in patients with renal impairment. Clin Pharmacol Ther. 2021;109(2):403&#8211;15.<pub-id pub-id-type="pmid">32705692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1998</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR60"><label>60.</label><citation-alternatives><element-citation id="ec-CR60" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rattanacheeworn</surname><given-names>P</given-names></name><name name-style="western"><surname>Kerr</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kittanamongkolchai</surname><given-names>W</given-names></name><name name-style="western"><surname>Townamchai</surname><given-names>N</given-names></name><name name-style="western"><surname>Udomkarnjananun</surname><given-names>S</given-names></name><name name-style="western"><surname>Praditpornsilpa</surname><given-names>K</given-names></name><etal/></person-group><article-title>Quantification of CYP3A and drug transporters activity in healthy young, healthy elderly and chronic kidney disease elderly patients by a microdose cocktail approach</article-title><source>Front Pharmacol</source><year>2021</year><volume>12</volume><fpage>726669</fpage><pub-id pub-id-type="doi">10.3389/fphar.2021.726669</pub-id><pub-id pub-id-type="pmid">34603040</pub-id><pub-id pub-id-type="pmcid">PMC8486002</pub-id></element-citation><mixed-citation id="mc-CR60" publication-type="journal">Rattanacheeworn P, Kerr SJ, Kittanamongkolchai W, Townamchai N, Udomkarnjananun S, Praditpornsilpa K, et al. Quantification of CYP3A and drug transporters activity in healthy young, healthy elderly and chronic kidney disease elderly patients by a microdose cocktail approach. Front Pharmacol. 2021;12: 726669.<pub-id pub-id-type="pmid">34603040</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fphar.2021.726669</pub-id><pub-id pub-id-type="pmcid">PMC8486002</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR61"><label>61.</label><citation-alternatives><element-citation id="ec-CR61" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bosilkovska</surname><given-names>M</given-names></name><name name-style="western"><surname>Samer</surname><given-names>CF</given-names></name><name name-style="western"><surname>D&#233;glon</surname><given-names>J</given-names></name><name name-style="western"><surname>Rebsamen</surname><given-names>M</given-names></name><name name-style="western"><surname>Staub</surname><given-names>C</given-names></name><name name-style="western"><surname>Dayer</surname><given-names>P</given-names></name><etal/></person-group><article-title>Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots</article-title><source>Clin Pharmacol Ther</source><year>2014</year><volume>96</volume><issue>3</issue><fpage>349</fpage><lpage>359</lpage><pub-id pub-id-type="doi">10.1038/clpt.2014.83</pub-id><pub-id pub-id-type="pmid">24722393</pub-id><pub-id pub-id-type="pmcid">PMC4151019</pub-id></element-citation><mixed-citation id="mc-CR61" publication-type="journal">Bosilkovska M, Samer CF, D&#233;glon J, Rebsamen M, Staub C, Dayer P, et al. Geneva cocktail for cytochrome P450 and P-glycoprotein activity assessment using dried blood spots. Clin Pharmacol Ther. 2014;96(3):349&#8211;59.<pub-id pub-id-type="pmid">24722393</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2014.83</pub-id><pub-id pub-id-type="pmcid">PMC4151019</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR62"><label>62.</label><citation-alternatives><element-citation id="ec-CR62" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Barone</surname><given-names>GW</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>J</given-names></name><name name-style="western"><surname>Breen</surname><given-names>P</given-names></name><name name-style="western"><surname>Yates</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans</article-title><source>Drug Metab Dispos</source><year>2006</year><volume>34</volume><issue>1</issue><fpage>69</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.1124/dmd.105.006312</pub-id><pub-id pub-id-type="pmid">16221754</pub-id><pub-id pub-id-type="pmcid">PMC1865121</pub-id></element-citation><mixed-citation id="mc-CR62" publication-type="journal">Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, et al. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2006;34(1):69&#8211;74.<pub-id pub-id-type="pmid">16221754</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.105.006312</pub-id><pub-id pub-id-type="pmcid">PMC1865121</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR63"><label>63.</label><citation-alternatives><element-citation id="ec-CR63" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Swain</surname><given-names>A</given-names></name><name name-style="western"><surname>Barone</surname><given-names>GW</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><name name-style="western"><surname>Breen</surname><given-names>P</given-names></name><name name-style="western"><surname>Yates</surname><given-names>CR</given-names></name><etal/></person-group><article-title>Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans</article-title><source>Drug Metab Dispos</source><year>2007</year><volume>35</volume><issue>2</issue><fpage>240</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1124/dmd.106.012708</pub-id><pub-id pub-id-type="pmid">17079360</pub-id><pub-id pub-id-type="pmcid">PMC1868501</pub-id></element-citation><mixed-citation id="mc-CR63" publication-type="journal">Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, et al. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos. 2007;35(2):240&#8211;5.<pub-id pub-id-type="pmid">17079360</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1124/dmd.106.012708</pub-id><pub-id pub-id-type="pmcid">PMC1868501</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR64"><label>64.</label><citation-alternatives><element-citation id="ec-CR64" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gurley</surname><given-names>BJ</given-names></name><name name-style="western"><surname>Swain</surname><given-names>A</given-names></name><name name-style="western"><surname>Williams</surname><given-names>DK</given-names></name><name name-style="western"><surname>Barone</surname><given-names>G</given-names></name><name name-style="western"><surname>Battu</surname><given-names>SK</given-names></name></person-group><article-title>Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John's wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics</article-title><source>Mol Nutr Food Res</source><year>2008</year><volume>52</volume><issue>7</issue><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="doi">10.1002/mnfr.200700081</pub-id><pub-id pub-id-type="pmid">18214850</pub-id><pub-id pub-id-type="pmcid">PMC2562898</pub-id></element-citation><mixed-citation id="mc-CR64" publication-type="journal">Gurley BJ, Swain A, Williams DK, Barone G, Battu SK. Gauging the clinical significance of P-glycoprotein-mediated herb-drug interactions: comparative effects of St. John&#8217;s wort, Echinacea, clarithromycin, and rifampin on digoxin pharmacokinetics. Mol Nutr Food Res. 2008;52(7):772&#8211;9.<pub-id pub-id-type="pmid">18214850</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/mnfr.200700081</pub-id><pub-id pub-id-type="pmcid">PMC2562898</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR65"><label>65.</label><citation-alternatives><element-citation id="ec-CR65" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Greiner</surname><given-names>B</given-names></name><name name-style="western"><surname>Eichelbaum</surname><given-names>M</given-names></name><name name-style="western"><surname>Fritz</surname><given-names>P</given-names></name><name name-style="western"><surname>Kreichgauer</surname><given-names>HP</given-names></name><name name-style="western"><surname>von Richter</surname><given-names>O</given-names></name><name name-style="western"><surname>Zundler</surname><given-names>J</given-names></name><etal/></person-group><article-title>The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin</article-title><source>J Clin Investig</source><year>1999</year><volume>104</volume><issue>2</issue><fpage>147</fpage><lpage>153</lpage><pub-id pub-id-type="doi">10.1172/JCI6663</pub-id><pub-id pub-id-type="pmid">10411543</pub-id><pub-id pub-id-type="pmcid">PMC408477</pub-id></element-citation><mixed-citation id="mc-CR65" publication-type="journal">Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, et al. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Investig. 1999;104(2):147&#8211;53.<pub-id pub-id-type="pmid">10411543</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI6663</pub-id><pub-id pub-id-type="pmcid">PMC408477</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR66"><label>66.</label><citation-alternatives><element-citation id="ec-CR66" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Reitman</surname><given-names>ML</given-names></name><name name-style="western"><surname>Chu</surname><given-names>X</given-names></name><name name-style="western"><surname>Cai</surname><given-names>X</given-names></name><name name-style="western"><surname>Yabut</surname><given-names>J</given-names></name><name name-style="western"><surname>Venkatasubramanian</surname><given-names>R</given-names></name><name name-style="western"><surname>Zajic</surname><given-names>S</given-names></name><etal/></person-group><article-title>Rifampin's acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug&#8211;drug interaction trial design</article-title><source>Clin Pharmacol Ther</source><year>2011</year><volume>89</volume><issue>2</issue><fpage>234</fpage><lpage>242</lpage><pub-id pub-id-type="doi">10.1038/clpt.2010.271</pub-id><pub-id pub-id-type="pmid">21191377</pub-id></element-citation><mixed-citation id="mc-CR66" publication-type="journal">Reitman ML, Chu X, Cai X, Yabut J, Venkatasubramanian R, Zajic S, et al. Rifampin&#8217;s acute inhibitory and chronic inductive drug interactions: experimental and model-based approaches to drug&#8211;drug interaction trial design. Clin Pharmacol Ther. 2011;89(2):234&#8211;42.<pub-id pub-id-type="pmid">21191377</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/clpt.2010.271</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR67"><label>67.</label><citation-alternatives><element-citation id="ec-CR67" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ding</surname><given-names>R</given-names></name><name name-style="western"><surname>Tayrouz</surname><given-names>Y</given-names></name><name name-style="western"><surname>Riedel</surname><given-names>KD</given-names></name><name name-style="western"><surname>Burhenne</surname><given-names>J</given-names></name><name name-style="western"><surname>Weiss</surname><given-names>J</given-names></name><name name-style="western"><surname>Mikus</surname><given-names>G</given-names></name><etal/></person-group><article-title>Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers</article-title><source>Clini Pharmacol Ther.</source><year>2004</year><volume>76</volume><issue>1</issue><fpage>73</fpage><lpage>84</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.02.008</pub-id><pub-id pub-id-type="pmid">15229466</pub-id></element-citation><mixed-citation id="mc-CR67" publication-type="journal">Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G, et al. Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clini Pharmacol Ther. 2004;76(1):73&#8211;84.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.02.008</pub-id><pub-id pub-id-type="pmid">15229466</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR68"><label>68.</label><citation-alternatives><element-citation id="ec-CR68" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Penzak</surname><given-names>SR</given-names></name><name name-style="western"><surname>Shen</surname><given-names>JM</given-names></name><name name-style="western"><surname>Alfaro</surname><given-names>RM</given-names></name><name name-style="western"><surname>Remaley</surname><given-names>AT</given-names></name><name name-style="western"><surname>Natarajan</surname><given-names>V</given-names></name><name name-style="western"><surname>Falloon</surname><given-names>J</given-names></name></person-group><article-title>Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes</article-title><source>Ther Drug Monit</source><year>2004</year><volume>26</volume><issue>3</issue><fpage>322</fpage><lpage>330</lpage><pub-id pub-id-type="doi">10.1097/00007691-200406000-00018</pub-id><pub-id pub-id-type="pmid">15167636</pub-id></element-citation><mixed-citation id="mc-CR68" publication-type="journal">Penzak SR, Shen JM, Alfaro RM, Remaley AT, Natarajan V, Falloon J. Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes. Ther Drug Monit. 2004;26(3):322&#8211;30.<pub-id pub-id-type="pmid">15167636</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1097/00007691-200406000-00018</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR69"><label>69.</label><citation-alternatives><element-citation id="ec-CR69" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>P</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>LA</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>KM</given-names></name><name name-style="western"><surname>George</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kellogg</surname><given-names>A</given-names></name><name name-style="western"><surname>McManus</surname><given-names>M</given-names></name><etal/></person-group><article-title>Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-Glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran</article-title><source>Antimicrob Agents Chemother</source><year>2017</year><volume>61</volume><issue>11</issue><fpage>11</fpage><pub-id pub-id-type="doi">10.1128/AAC.01201-17</pub-id><pub-id pub-id-type="pmcid">PMC5655101</pub-id><pub-id pub-id-type="pmid">28848011</pub-id></element-citation><mixed-citation id="mc-CR69" publication-type="journal">Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, et al. Differential influence of the antiretroviral pharmacokinetic enhancers ritonavir and cobicistat on intestinal P-Glycoprotein transport and the pharmacokinetic/pharmacodynamic disposition of dabigatran. Antimicrob Agents Chemother. 2017;61(11):11.<pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/AAC.01201-17</pub-id><pub-id pub-id-type="pmcid">PMC5655101</pub-id><pub-id pub-id-type="pmid">28848011</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR70"><label>70.</label><citation-alternatives><element-citation id="ec-CR70" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hamman</surname><given-names>MA</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SM</given-names></name><name name-style="western"><surname>Lesko</surname><given-names>LJ</given-names></name><name name-style="western"><surname>Hall</surname><given-names>SD</given-names></name></person-group><article-title>Effect of St John's wort on the pharmacokinetics of fexofenadine</article-title><source>Clin Pharmacol Ther</source><year>2002</year><volume>71</volume><issue>6</issue><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="doi">10.1067/mcp.2002.124080</pub-id><pub-id pub-id-type="pmid">12087344</pub-id></element-citation><mixed-citation id="mc-CR70" publication-type="journal">Wang Z, Hamman MA, Huang SM, Lesko LJ, Hall SD. Effect of St John&#8217;s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther. 2002;71(6):414&#8211;20.<pub-id pub-id-type="pmid">12087344</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1067/mcp.2002.124080</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR71"><label>71.</label><citation-alternatives><element-citation id="ec-CR71" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arold</surname><given-names>G</given-names></name><name name-style="western"><surname>Donath</surname><given-names>F</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>A</given-names></name><name name-style="western"><surname>Diefenbach</surname><given-names>K</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Henneicke-von Zepelin</surname><given-names>HH</given-names></name><etal/></person-group><article-title>No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John's wort extract</article-title><source>Planta Med</source><year>2005</year><volume>71</volume><issue>4</issue><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="doi">10.1055/s-2005-864099</pub-id><pub-id pub-id-type="pmid">15856409</pub-id></element-citation><mixed-citation id="mc-CR71" publication-type="journal">Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, et al. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John&#8217;s wort extract. Planta Med. 2005;71(4):331&#8211;7.<pub-id pub-id-type="pmid">15856409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1055/s-2005-864099</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR72"><label>72.</label><citation-alternatives><element-citation id="ec-CR72" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Johne</surname><given-names>A</given-names></name><name name-style="western"><surname>Brockmoller</surname><given-names>J</given-names></name><name name-style="western"><surname>Bauer</surname><given-names>S</given-names></name><name name-style="western"><surname>Maurer</surname><given-names>A</given-names></name><name name-style="western"><surname>Langheinrich</surname><given-names>M</given-names></name><name name-style="western"><surname>Roots</surname><given-names>I</given-names></name></person-group><article-title>Pharmacokinetic interaction of digoxin with an herbal extract from St John's wort (Hypericum perforatum)</article-title><source>Clin Pharmacol Ther</source><year>1999</year><volume>66</volume><issue>4</issue><fpage>338</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1053/cp.1999.v66.a101944</pub-id><pub-id pub-id-type="pmid">10546917</pub-id></element-citation><mixed-citation id="mc-CR72" publication-type="journal">Johne A, Brockmoller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John&#8217;s wort (Hypericum perforatum). Clin Pharmacol Ther. 1999;66(4):338&#8211;45.<pub-id pub-id-type="pmid">10546917</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1053/cp.1999.v66.a101944</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR73"><label>73.</label><citation-alternatives><element-citation id="ec-CR73" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zahner</surname><given-names>C</given-names></name><name name-style="western"><surname>Kruttschnitt</surname><given-names>E</given-names></name><name name-style="western"><surname>Uricher</surname><given-names>J</given-names></name><name name-style="western"><surname>Lissy</surname><given-names>M</given-names></name><name name-style="western"><surname>Hirsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Nicolussi</surname><given-names>S</given-names></name><etal/></person-group><article-title>No clinically relevant interactions of St. John's Wort extract Ze 117 low in hyperforin with cytochrome p450 enzymes and P-glycoprotein</article-title><source>Clin Pharmacol Ther</source><year>2019</year><volume>106</volume><issue>2</issue><fpage>432</fpage><lpage>440</lpage><pub-id pub-id-type="doi">10.1002/cpt.1392</pub-id><pub-id pub-id-type="pmid">30739325</pub-id><pub-id pub-id-type="pmcid">PMC6766782</pub-id></element-citation><mixed-citation id="mc-CR73" publication-type="journal">Zahner C, Kruttschnitt E, Uricher J, Lissy M, Hirsch M, Nicolussi S, et al. No clinically relevant interactions of St. John&#8217;s Wort extract Ze 117 low in hyperforin with cytochrome p450 enzymes and P-glycoprotein. Clin Pharmacol Ther. 2019;106(2):432&#8211;40.<pub-id pub-id-type="pmid">30739325</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/cpt.1392</pub-id><pub-id pub-id-type="pmcid">PMC6766782</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR74"><label>74.</label><citation-alternatives><element-citation id="ec-CR74" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mueller</surname><given-names>SC</given-names></name><name name-style="western"><surname>Uehleke</surname><given-names>B</given-names></name><name name-style="western"><surname>Woehling</surname><given-names>H</given-names></name><name name-style="western"><surname>Petzsch</surname><given-names>M</given-names></name><name name-style="western"><surname>Majcher-Peszynska</surname><given-names>J</given-names></name><name name-style="western"><surname>Hehl</surname><given-names>EM</given-names></name><etal/></person-group><article-title>Effect of St John's wort dose and preparations on the pharmacokinetics of digoxin</article-title><source>Clin Pharmacol Ther</source><year>2004</year><volume>75</volume><issue>6</issue><fpage>546</fpage><lpage>557</lpage><pub-id pub-id-type="doi">10.1016/j.clpt.2004.01.014</pub-id><pub-id pub-id-type="pmid">15179409</pub-id></element-citation><mixed-citation id="mc-CR74" publication-type="journal">Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl EM, et al. Effect of St John&#8217;s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther. 2004;75(6):546&#8211;57.<pub-id pub-id-type="pmid">15179409</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.clpt.2004.01.014</pub-id></mixed-citation></citation-alternatives></ref><ref id="CR75"><label>75.</label><citation-alternatives><element-citation id="ec-CR75" publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Van Hemelryck</surname><given-names>S</given-names></name><name name-style="western"><surname>Van Landuyt</surname><given-names>E</given-names></name><name name-style="western"><surname>Ariyawansa</surname><given-names>J</given-names></name><name name-style="western"><surname>Palmer</surname><given-names>M</given-names></name><name name-style="western"><surname>Kothe</surname><given-names>MJC</given-names></name><name name-style="western"><surname>Pollefliet</surname><given-names>C</given-names></name></person-group><article-title>Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults</article-title><source>AAPS Open</source><year>2024</year><volume>10</volume><issue>1</issue><fpage>10</fpage><pub-id pub-id-type="doi">10.1186/s41120-024-00097-w</pub-id></element-citation><mixed-citation id="mc-CR75" publication-type="journal">Van Hemelryck S, Van Landuyt E, Ariyawansa J, Palmer M, Kothe MJC, Pollefliet C. Pharmacokinetic interaction between single and multiple doses of darunavir, in combination with cobicistat or ritonavir, and single-dose dabigatran etexilate in healthy adults. AAPS Open. 2024;10(1):10.</mixed-citation></citation-alternatives></ref></ref-list></back></article></pmc-articleset>